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RESUMEN EN CASTELLANO 
El ADN está expuesto a muchos tipos de daño durante la vida de un 
organismo. La mayor parte de las lesiones son detectadas y reparadas sin llegar a 
comprometer la viabilidad celular. Sin embargo, ciertos tipos de daño pueden 
poner en peligro la integridad del genoma. Durante la replicación, por ejemplo, se 
pueden dar gran variedad de lesiones que darán lugar a lo que conocemos como 
estrés replicativo. Si la cantidad de daño excede unos determinados límites, se 
activarán programas de apoptosis o senescencia celular que pueden comprometer 
la capacidad regenerativa de los tejidos y derivar en patologías asociadas al 
envejecimiento. 
Así pues, mantener la integridad del genoma es fundamental para cada una 
de nuestras células.  Sin embargo, a diferencia de otras proteínas y 
macromoléculas, no existe un recambio constante de ADN, lo que hace 
fundamentales la precisa detección, señalización y reparación de cualquier tipo de 
daño. Toda esta respuesta se denomina Respuesta al Daño en el ADN y está 
regulada por las quinasas ATM y ATR. Estas proteínas comienzan una cascada de 
fosforilaciones que logra establecer diferentes puntos de control en el ciclo celular. 
Estos puntos de control ralentizarán el ciclo celular, lo que dejará tiempo para 
reparar el daño en el ADN. 
El estrés replicativo es un tipo especial de daño que ha sido asociado al 
envejecimiento y al cáncer; y que es controlado por la quinasa ATR. En ratones, la 
reducción de los niveles de ATR en un modelo del síndrome de Seckel se traduce 
en un incremento de los niveles de estrés replicativo y envejecimiento acelerado. 
Del mismo modo, los fibroblastos embrionarios derivados de este modelo murino 
acumulan estrés replicativo y entran en senescencia de forma prematura. En 
trabajos anteriores de este laboratorio se demostró que la eliminación de p53 no 
logra rescatar esta senescencia. Sin embargo, en esta tesis doctoral probamos 
cómo la deleción genética del locus INK4a/ARF logra rescatar por completo no 
sólo la senescencia prematura de los fibroblastos de ATR-Seckel, sino también la 
inducida por otras condiciones que generan estrés replicativo, como dosis bajas de 
hidroxiurea o inhibidores de ATR. Además, demostramos que una exposición 
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constante a estrés replicativo induce la expresión de  los productos del locus 
INK4a/ARF; lo que revela que este locus se comporta como un punto de control del 
estrés replicativo.  
En resumen, mediante el empleo de diferentes técnicas de biología molecular 
(Western Blot, Southern Blot, inmunofluorescencias…), biología celular 
(infecciones, estudios de la proliferación y ciclo celular…) y modelos animales,  
nuestros datos revelan un nuevo papel para el locus INK4a/ARF en la limitación de 
la expansión de células que sufren una exposición repetida al estrés replicativo.  De 
este modo, logramos establecer un nuevo enlace entre el conocido supresor 
tumoral INK4a/ARF y el mantenimiento de la integridad genómica.
Abstract 
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ABSTRACT 
During our lifetime, DNA encounters many kinds of damage, both from 
endogenous and exogenous origin. Most lesions are detected and repaired without 
compromising cell viability. However, there are special types of damage that can 
endanger genome integrity. During replication, for instance, a wide range of lesions 
can occur. The different types of damage that appear during DNA replication give 
rise to Replication Stress (RS).  If the amount of damage is over a certain threshold, 
cells can activate apoptotic and/or senescence programs, which can compromise 
the regenerative ability of tissues and lead to ageing related pathologies. This way, 
the integrity of the genome is a crucial event in the life of every cell. Nevertheless, 
unlike proteins and other molecules, DNA is not replaced. Thus, proper detection 
of DNA damage, precise signaling and potent repair machineries are needed. The 
response that cells establish upon DNA damage is what we call the DNA Damage 
Response (DDR). Protein kinases such us ATM and ATR are the key activators of 
this transduction pathway. They start a phosphorylation cascade in order to 
establish the different cell cycle checkpoints, which will slow down the cell cycle,  
leaving time for DNA repair.  
Replication stress is a particular source of DNA damage that has been linked 
to cancer and ageing, and which is suppressed by the ATR kinase. In mice, reduced 
ATR levels in a model of the ATR-Seckel Syndrome lead to RS and accelerated 
ageing. Similarly, ATR-Seckel embryonic fibroblasts (MEF) accumulate RS and 
undergo cellular senescence. We previously showed that senescence of ATR-Seckel 
MEF cannot be rescued by p53-deletion. In this thesis work we show that the 
genetic ablation of the INK4a/ARF locus fully rescues senescence on ATR mutant 
MEF, but also that induced by other conditions that generate RS, such us low doses 
of HU or ATR inhibitors. In addition, we show that a persistent exposure to RS 
leads to increased levels of INK4a/ARF products, revealing that INK4a/ARF 
behaves as a bona fide RS- checkpoint. Our data revealed an unknown role for 
INK4a/ARF in limiting the expansion of cells suffering from persistent replication 
stress, linking this well-know tumor suppressor to the maintenance of genomic 
integrity. 
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INTRODUCTION 
A. DNA DAMAGE 
Our genetic material is exposed to continuous aggressions. One of the main 
biological functions of a cell is to maintain genome integrity. DNA lesions have 
been related to different aspects of human physiology and pathology. The most 
obvious one, due to its capacity to mutagenise, is cellular transformation and 
cancer development (Hanahan and Weinberg, 2000). Another one is the loss of 
regenerative potential in different tissues, by the reduction of their proliferative 
rates, what leads to ageing of the whole organism (Garinis et al., 2008). DNA 
damage has also been related to a wide range of illnesses such as 
neurodegenerative diseases, immunodeficiencies, or sterility (Jackson and Bartek, 
2009).  But DNA damage is also the driving force of evolution. DNA lesions are 
fundamental to boost the small variations in our genetic material that allow the 
wide adaptative range required for evolution (Stamatoyannopoulos et al., 2009).  
There are a great variety of DNA lesions: from lack of complementarity of a 
pair of nucleotides, to the breakage of one or both of the DNA strands, lesions from 
exogenous or endogenous sources… And we need to take into account that 
chromosomes, unlike other cellular components, cannot be replaced. Therefore, a 
complex protein network that detects, signals and repairs any damage in the DNA 
is essential for the cell. 
1. Sources of DNA Damage 
1.1.Exogenous damage 
Most exogenous sources of DNA damage come in the form of radiations that 
are able to penetrate membranes and tissues, reaching the cell nucleus and causing 
different lesions. We can classify radiations by their mechanism of action in two 
types: ionizing and non ionizing radiation.  
Ionizing radiations, like X rays, gamma () radiation and electromagnetism, 
can generate single strand or double strand breaks in the DNA helix (Lindahl and 
Barnes, 2000). They can also generate reactive oxygen species (ROS) upon their 
Introduction 
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impact in water, which will give rise to clustered DNA breaks along the radiation 
path (Hoeijmakers, 2001).  
Non ionizing radiation is less potent, and therefore less damaging to DNA. 
However, we are exposed to it every day, since one type is ultraviolet (UV) 
radiation. Even though the ozone layer blocks most of the UV rays, part of the 
radiation is able to go through it and impact our skin, giving rise to highly stable 
and mutagenic covalent bonds that form pirimidine’s dimmers (Jiang et al., 2009).  
Besides the influence of radiations, there are several chemicals that we can 
be exposed to accidentally, or in purpose; such as in the case of many of the 
chemotherapies used in cancer treatment. 
Still nowadays, cancer is still treated with surgery, radiotherapy and classical 
chemotherapy. Both, classical chemotherapy and radiation are based on the 
generation of DNA damage and the consequent activation of apoptosis or 
senescence pathways in order to kill cancer cells (Toledo et al., 2011a). Through 
their use, both cancer and healthy cells will incorporate some damage in their DNA, 
which in some occasions contribute to relapses or secondary tumors. However, 
cancer cells usually have high proliferation rates, what makes them particularly 
sensitive to DNA damage inducing agents. In contrast, healthy cells do not grow – 
most cells in a tissue are in G0 or G1- or grow at a slower rate, what keeps them 
somewhat protected from DNA damage. 
1.2. Endogenous damage 
A great portion of the DNA damage that we are exposed to and that is 
relevant to mutagenesis, carcinogenesis and aging is of endogenous origin. More 
specifically there are three main types of endogenous damage: reactive oxygen 
species (ROS), eroded telomeres and replication stress. There are also 
spontaneous changes in DNA bases, approximately 107 a day in a standard human 
body (Lindahl and Barnes, 2000). 
But DNA is not only broken accidentally. DNA damage repair, as well as other 
physiological processes – like meiosis or limphocyte maturation - selectively 
produces DSBs. During meiotic recombination, chromosomes are broken in a 
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control fashion in order to interchange sequences with their homolog. This process 
increases the variability in gamete’s genome (Zickler and Kleckner, 1998). 
Moreover, during class switching and V(D)J recombination there are different 
somatic recombination events that also require DNA breakage and reapair (Dudley 
et al., 2005). Accordingly, mutations in proteins implicated in DNA repair, in many 
cases lead to immune and fertility problems (Jackson and Bartek, 2009). 
1.2.1. Reactive oxygen species (ROS) 
Reactive oxygen species (ROS) are chemically reactive molecules containing 
oxygen. The most dangerous ROS are the superoxide ion, hydrogen peroxide and 
the hydroxyl radical (De Bont and van Larebeke, 2004). In aerobic organisms the 
energy needed to for biological functions is produced in the mitochondria via the 
electron transport chain (Han et al., 2001). In addition to energy, ROS are also 
produced in this process. ROS can damage RNA, proteins and DNA - giving rise to 
single strand breaks (DNA nicks) and double strand breaks (DSBs) - what in 
theory, contributes to the physiology of ageing. 
1.2.1. Eroded telomeres 
Eroded telomeres are another important source of endogenous DNA damage. 
Telomeres are highly conserved structures, which function is to protect and 
stabilize the end of the chromosomes. Telomere erosion makes the cell unable to 
distinguish between a DSB and a normal telomere end. This causes irregular 
fusions and recombinations, that lead to chromosomal aberrations (Ludérus et al., 
1996). Telomere erosion is due to the inability of DNA polymerases to completely 
replicate the 5’ DNA end. Therefore, telomeres suffer a shortening that varies 
between 50- 200 base pairs in every cell division (Martens et al., 2000). This 
telomere shortening behaves like a biological clock that regulates the proliferative 
potential of every cell. Once a certain critique telomere length is reached, cells 
usually enter senescence. If they continue to proliferate, they will be predisposed 
to telomere fusions and genomic instability that could eventually lead to genetic 
disorders (Günes and Rudolph, 2013).  
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1.2.3. Replication stress 
Replication stress (RS) is a not very well defined concept that refers to a 
diversity of alterations in the normal progression of the replication fork, caused by 
lesions encountered in the DNA, dNTPs deficiency or other problems at the 
replication fork. When RS is prolonged or, in the absence of ATR, the replication 
fork collapse and DSB are generated. Importantly, there is no such a thing as RS-
free replication. Thus, RS repair pathways are essential, even in the absence of 
exogenous DNA damage. 
Somehow it is believed that DNA synthesis magnifies the common effects of 
DNA damage (Ruzankina et al., 2008). For instance, a mutation in one single base 
that does not pair properly with its complementary one, will only give rise to a 
transitory ssDNA stretch during G1. However, the same mutation during S phase 
can lead to replication fork stall, which could eventually generate multiple DSBs.  
Part of the errors that can occur during replication may be due the 
incorporation of the wrong nucleotide or a chemically modified one. Proof reading 
and Mismatch Repair (MMR) look after these mistakes and correct them during the 
replication process (Fu et al., 2012).  
Also, in order to duplicate DNA content, replication forks need to unwind the 
double helix. Thus, ssDNA is constantly being exposed during this process. Any 
obstacle that blocks the advance of the replication machinery during this 
unwinding step, will give rise to long stretches of ssDNA; putting in risk DNA 
integrity (Paulsen and Cimprich, 2007). 
In addition to this, loss of function of some components of the replication 
machinery can cause tension in the replication fork, which may lead to a DNA 
break. Topoisomerases are enzymes that are able to wind and/or unwind DNA. 
Some of them are responsible for releasing the tension caused by the characteristic 
supercoilling found in the front part of the replication fork (Koster et al., 2010). 
Their way of action implies cutting and pasting DNA, what makes them a potential 
source of DNA breaks. If the ligase activity of topoisomerases is blocked, they will 
not be able to repair the breaks that they have already made (D'Arpa et al., 1990). 
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Importantly, activation of oncogenes has recently been postulated as a source 
of replication stress. The first evidences revealed an activation of the DDR in 
precancerous lesions and cancer (Bartkova et al., 2005; Gorgoulis et al., 2005). 
Later on, and consistent with the previous observation, oncogene activation was 
proven to generate replication stress and senescence (Bartkova et al., 2006; 
Gorrini et al., 2007). In principle,  the activation of oncogenes increases replication 
rates. These high replication rates can compromise replication control 
mechanisms, causing a greater ssDNA exposition and even DSBs. The underlying 
mechanism behind RS accumulation due to oncogene activation is not fully 
understood. Recent works propose that the activation of oncogenes induces RS 
through increased firing of replication origins, what leads to an insufficient 
nucleotide pool unable to support normal replication and genome stability (Beck 
et al., 2012; Bester et al., 2011; Poli et al., 2012). Consistently, addition of 
nucleosides counteracts the effects of oncogene activation on fork speed and DSB 
formation (Beck et al., 2012). 
Altogether, these events would contribute to the characteristic genomic 
instability observed in most human cancers. This constant basal damage caused by 
oncogene activation is able to activate the DDR through the ATR and ATM kinases. 
Figure 1. DNA damage 
sources. There are different 
sources of DNA damage that can 
alter the structure and function 
of DNA. DNA damage sources 
can be classified according to 
their origin in exogenous and 
endogenous sources. Different 
types of DNA damage can arise 
from these sources: from simple 
nicks or nucleotides alterations 
to single strand or double strand 
breaks, being these last ones the 
more severe ones. 
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2. The DNA Damage Response (DDR) 
When a cell detects damage in its DNA, it activates a response that leads to 
DNA damage repair in order to keep genome integrity (Harper and Elledge, 2007). 
DNA damage Response refers to the group of processes that allow DNA repair, cell 
cycle control and, depending on the cell type or the amount of DNA damage, the 
induction of apoptosis or senescence. The type of response depends on the type of 
damage. Most of the lesions are repaired without affecting cell cycle control. 
However, in certain occasions the amount damage is high and/or the type of lesion 
severe and a cell cycle stop signal is activated. This stop signal is known as 
checkpoint and it delays the entry into the next phase of the cell cycle.  There are 
cases in which the damage exceeds the repair capacity of the cell. In this situation, 
and depending on the cell type, healthy cells activate either a cell death program – 
apoptosis - or an irreversible stop program – senescence - . The most severe types 
of DNA damage that a cell can suffer are ssDNA and DSBs accumulation. ssDNA 
stretches are a highly recombinogenic structures and DSBs can cause 
chromosomal translocations and/or fusions. These events will lead to an improper 
segregation during mitosis, with the possible loss of genetic material or complete 
mitotic failure and catastrophic dead. In this scenario, most cells will die. However, 
low amounts of DNA damage can promote cellular transformation and the onset of 
cancer, by inducing the expression of oncogenes or the loss of tumor suppressors.  
The DDR is a hierarchical process that activates several groups of proteins in 
a specific order (Figure 2). These proteins take care of the different tasks needed to 
repair DNA damage (Shiloh, 2003). First of all, lesions are detected by sensing 
proteins that stay near chromatin. Next, break ends are processed to gain a 
recognizable structure that can serve as a substrate for the different repair 
mechanisms.  After this, the signal is transmitted through transducers. At this 
stage, the signal is diversified by the action of a variety of modulators and 
adaptators that spread it throughout the whole nucleus until it reaches effectors. 
Effectors will finally carry out the necessary actions to repair the damage. Finally, 
the entire signaling cascade must be turn off and return to its basal state, mainly 
thanks to the action of phosphatases (Bakkenist and Kastan, 2004). 
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Figure 2. DDR hierarchy. Different types of damage are initially recognized by sensors, that 
recruit transducers to trigger the signal. This signal is amplified by mediators. Mediators guide the 
signal until it reaches effectors, in charge of executing the appropriate response.  
3. Detecting the lesion and initiating the signal: DDR sensors and 
transducers 
As mentioned before, DNA damage signaling starts with the recognition of 
the lesion, accomplished by sensors. These proteins are in constant contact with 
chromatin. Sensors are activated upon different types of damage and have an 
essential role in the activation of the DDR (Zou et al., 2002).  
The most significative transducers of the DDR are three kinases: ATM (Ataxia 
Telangiectasia Mutated), ATR (ATM and Rad3 related), and DNA-PKcs (DNA 
protein kinase catalytic subunit).  
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3.1. DNA damage Kinases 
ATM, ATR and DNA-PKcs transmit the DNA damage signal, mainly, by the 
most common post translational modification: phosphorylation. ATM, ATR and 
DNA-PKcs, together with mTOR, SMG1 and TRRAP, are part of the 
phosphatidylinositol-3-kinase like (PIKK) family (Shiloh, 2003). ATM, ATR and 
DNA-PKcs are high molecular weight proteins in which the kinase domain is highly 
conserved. In contrast to PI3K, which phosphorylate lipids, PIKKs exclusively 
phosphorylate proteins in their serine and treonine residues, preferentially when 
they are followed by a glutamic acid -(S/T)Q-.  Their kinase domain represents 
only about 5-10% of the protein, which leaves the majority of it to regulatory 
functions. All these three proteins have a similar structure: a long aminoterminal 
region with several HEAT (Huntingtin, Elongation factor 3, a subunit of protein 
phosphatase 2A, and TOR1) repeats, a caboxiterminal region composed by FACTC 
(FACT C-terminal), and a kinase (catalytic domain PI3K), PRD (PiKK Regulatory 
Domain) and FAT (FRAP, ATM and TRRAP) domains.  
Despite the structural similarities between ATM, ATR and DNA-PKcs, they all 
have different functions. On the one hand, ATM and DNA-PKcs are activated in 
response to DSBs in every phase of the cell cycle (Gottlieb and Jackson, 1993; 
Pandita et al., 2000). On the other hand, ATR is responsible for signaling ssDNA 
and its activity is restricted to S and G2 phases (Zou and Elledge, 2003). Finally, 
DNA-PKcs activity is restricted to the site of the lesion and it mainly promotes DSB 
repair (Collis et al., 2005), while ATM and ATR have an essential role in the global 
signaling of damage. 
 3.1.1DNA PKcs 
DNA-PKcs is attracted to the break site by the damage sensor Ku70/Ku80 
heterodimer, a DSB sensor that binds to DNA ends and stabilizes them (Smith and 
Jackson, 1999). The complex  Ku70/ku80/DNA-PKcs forms a catalytically active 
kinase DNA-PK (Gottlieb and Jackson, 1993), that promotes DSB repair through 
Non Homologous End Joining (NEHJ) (Mahaney et al., 2009). NHEJ consists of the 
approaching and later ligation of two DNA ends with the need of very little or no 
homology. Although DNA-PK kinase activity is restricted to the damage site it can 
phosphorylate certain substrates in common with ATM and ATR. This fact 
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increases the signaling capacity of ATM and ATR and attracts other mediators to 
the lesion (Stiff et al., 2004). Also, a recent work shows that DNA-PK can replace 
some of the functions of ATM when the later is absent, such as H2AX or p53 
phosphorylation (Callén et al., 2009). 
3.1.2. ATM 
The ATM mediated response is initiated by the complex Mre11- Rad50-Nbs1 
(MRN) (Lee and Paull, 2005; Petrini and Stracker, 2003). This complex recruits 
ATM and collaborates for its activation (Uziel et al., 2003). However, the exact 
mechanism by which ATM is activated is still a matter of debate (Lavin, 2008). One 
group proposed that, in basal conditions, ATM is an inactive homodimer which is 
dissociated and activated in response to DSB, due to its autophosphorylation 
(Bakkenist and Kastan, 2003). Of note, it has later been shown that ATM 
autophosphorylation is not necessary for its activation in vivo (Daniel et al., 2008). 
Although DNA-PK is the main kinase promoting DSB repair, it has been 
proposed that ATM also contributes to this process, especially when the break lies 
in heterochromatin. The repair of heterochromatic DSBs is slower and more 
difficult and ATM has been reported to be able to  phosphorylate certain substrates 
in order to increase chromatin accessibility (Goodarzi et al., 2008). However, ATM 
is essential for repair during meiosis, and meiotic DSBs are thought to be 
generated within accessible chromatin domains. Also, AT patients, develop 
progressive degeneration of cerebellar Purkinje neurons, in which chromatin is 
highly euchromatic. Thus, the importance of ATM-mediated facilitation of DSB 
repair in heterochromatin is still a matter of debate  (Fernandez-Capetillo and 
Nussenzweig, 2008).   
3.1.3. ATR 
In contrast to ATM, ATR is an essential protein at the cellular and organism 
level (Brown and Baltimore, 2000). ATR is activated in response to abnormally 
long ssDNA regions, which can appear at S or G2 phase. ssDNA in S phase can be a 
consequence of the uncoupling between the replication machinery and the 
movement of the replicative helicases (Byun et al., 2005).  However, ssDNA can 
also appear as a byproduct of DBS resection during S and G2 phases (Raynard et 
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al., 2008). Replication forks can be blocked in response to DNA alterations. In this 
scenario, ATR activity maintains the stability of the replication complexes so that 
they can re-start DNA synthesis when the problem is solved (Paulsen and 
Cimprich, 2007). ATR exists only as part of a heterodymeric complex with ATRIP 
(ATR interacting protein). ATRIP is necessary for ATR signaling activity and it is 
responsible for the correct loading of ATR to ssDNA sites (Cortez et al., 2001). The 
ATR-ATRIP complex needs to be activated by interaction with TopBP1 
(Topoisomerase II binding protein). TopBP1 functions as an allosteric inductor of 
ATR’s kinase domain (Kumagai et al., 2006). This allosteric inductor only interacts 
with the ATR-ATRIP complex when the three of them are recruited to ssDNA, what 
ultimately triggers ATR kinase activity.  
This complex control mechanism is possible because different sensors are in 
charge of attracting ATR-ATRIP and TopBP1 to ssDNA. On one hand, Replication 
Protein A (RPA) coats ssDNA stabilizing it and attracting ATR-ATRIP (Walter and 
Newport, 2000) and Rad17. Independently, Rad 17 interacts with the Replication 
Factor C and loads 9-1-1 (Rad9, Hus1, Rad1) (Bermudez et al., 2003) to the double 
stranded DNA adjacent to the RPA coated ssDNA (Zou et al., 2002). Finally the 9-1-
1 complex would recruit TopBP1, thus bringing it into close proximity to ATR. In 
addition to this, recent data have shown that TopBP1 is also recruited to 
ssDNA/dsDNA junctions through interactions with Nbs1 (Duursma et al., 2013). 
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Figure 3. ATM and ATR activation mechanism A) ATR and TopBP1 are recruited to ssDNA by 
RPA and –possibly- the MRN complex. TopBP1 activates ATR, which triggers the corresponding 
phosphorylation cascade. B) ATM goes to DSB attracted by the MRN complex. H2AX 
phosphorylation recruits MDC1 and amplifies ATM signal. Modified from (Cimprich and Cortez, 
2008) 
3.2. Human diseases related to the DDR Kinases 
3.2.1. SCID 
The absence of DNA-PKcs activity in mouse results in severe combined 
immunodeficiency (SCID), a profound defect in the mouse immune system that is 
accompanied by ionizing radiation hypersensibility (Smith and Jackson, 1999), 
((Biedermann et al., 1991). In humans SCID can appear due to defects in different 
proteins that lead to a severe immunodeficiency (Buckley, 2004). 
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3.2.2. Ataxia - Telangiectasia 
Lack of ATM activity was identified as the cause of Ataxia-Telangiectasia (A-
T) (Savitsky et al., 1995), a recesive autosomal disease. A-T patients present every 
sign of a deficiency in DSB repair: immunodeficiency, genomic instability, 
predisposition to cancer of lymphoid origin and ionizing radiation hypersensitivity 
(Becker-Catania and Gatti, 2001; Shiloh and Kastan, 2001). In addition, ATM 
mutations are frequent in cancer (Vorechovský et al., 1996). 
3.2.3. Seckel Syndrome 
Seckel syndrome (SS) is a congenital autosomic rare disease. It is 
characterized by a delay in intrauterine development, mental retardation, 
microcephaly, proportional dwarfism and a characteristic craniofacial 
malformation that includes a receding forehead and micrognatia (O'Driscoll et al., 
2003), which confers patients a peculiar face. This last sign was what allowed 
Rudolf Wirchow, who described the illness for the first time in 1892, to call it “Bird 
Headed Dwarfism”. Later on, in 1960, Helmut Seckel characterized the whole 
syndrome in depth. It is estimated that less than 1/10.000 births suffer this 
syndrome, affecting women and men and without any ethnic or geographic 
predominance. 
Apart from the previously mentioned signs, patients show a progeroid 
appearance and dwarfism, frequent hallmarks of genomic instability syndromes. 
The syndrome has a complicated etiology; mutations in different loci contribute to 
the same symptoms. It was not until 2003 when the first genetic defect was 
associated to the Seckel syndrome: a mutation in ATR (O'Driscoll et al., 2003). 
In studies in several families with SS, some residual ATR activity was 
detected. This was enough to allow patient viability, although with severe clinical 
consequences (O'Driscoll et al., 2003). The study of cellular lines obtained from 
patients’ skin identified a point mutation (2101A-G) that affects ATR splicing. The 
mutation described, localized at the beginning of exon 9, generates an aberrant 
non-functional protein. However, the patients still express about 5% of normal 
ATR protein levels, what allows their survival. Based on this mutation, a mouse 
model of the Seckel Syndrome was developed in our lab (Murga et al., 2009). ATR- 
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Seckel mice are dwarf and die prematurely due to a pleotropic progeroid disease. 
In addition, these mice present the same craniofacial abnormalities describe on the 
patients. Thus, ATR-Seckel mice provide an excellent model for the study of ATR 
function in mammals. 
4. Amplifying the signal: mediators 
In order to spread the alarm signal and orchestrate the global cellular 
response to DNA damage, ATR and ATM cooperate very tightly with other proteins. 
At this level, mediators play an essential role: they are proteins with very diverse 
functions that modulate ATR and ATM activity. Mediators regulate the 
spatiotemporal assembly of protein complexes in the chromatin regions next to the 
lesion (Kastan and Bartek, 2004). Many of the mediator proteins share the capacity 
to be loaded into DNA and be concentrated on DSBs or ssDNA in protein 
aggregates that can be visualized by immunoflorescence as foci.  
In response to IR, many of these proteins form ionizing radiation induced foci 
(IRIF). In fact, many of the components of the DDR colocalize at foci that present an 
accumulation of phosphorylated H2AX (H2AX). H2AX is phosphorylated by ATM, 
ATR and DNA-PKcs through megabases of DNA (Rogakou et al., 1998). After the 
phosphorylation of histone H2AX in its serine 139, MDC1 is recruited through 
direct phosphobinding. Altogether, these events recruit additional proteins from 
the ATM pathway, amplifying the signal.  According to the current model, although 
most of the mediators are recruited to the lesion in a H2AX independent manner, 
their accumulation at foci depends on the phosphorylation of H2AX by ATM 
(Celeste et al., 2003). 
Phosphorylation is not the only modification that recruits factors to foci. For 
instance, BRCA1 and 53BP1recruitment depends on histone ubiquitination by 
RNF8 or RNF 168 (van Attikum and Gasser, 2009). Additionally, when ssDNA is 
exposed, RPA is accumulated coating the single strand in a H2AX independent 
fashion. 
Of note, protein accumulation at foci is a posterior and functionally distinct 
process to protein recruitment to damaged regions. In the absence of H2AX or 
MDC1, fundamental factors of the DDR, like 53BP1or BRCA1 cannot longer form 
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foci.  However, this does not have severe consequences because they maintain 
their ability to go to DSBs (Celeste et al., 2003; Celeste et al., 2002; Stewart et al., 
2003)). One possible explanation for this is that foci just facilitate an efficient 
signaling of the damage (Fernandez-Capetillo et al., 2002) which is critical when 
only a few breaks are present. That is, the concentration of mediators in a 
particular area avoids that they uncouple from chromatin before the damage has 
been repaired (Kruhlak et al., 2006a; Kruhlak et al., 2006b).   
5. Executing the response: effectors  
The execution of the signal generated by ATM and ATR in response to DNA 
damage is carried out by two effector kinases: CHK1 and CHK2. ATM specifically 
phosphorylates CHK2 in its treonine 68 (Matsuoka et al., 1998) and ATR 
phosphorylates CHK1 in its serines 317 and 345 (Zhao and Piwnica-Worms, 2001). 
Altogether, the four kinases constitute the main guides to stop the cell cycle in 
response to DNA damage. Although they are under the control of ATM and ATR, 
CHK1 and CHK2 kinases are essential for the correct activation of the different 
checkpoints. In fact, whereas CHK1 is phophorylated at the break site, it then 
spreads to the whole nucleoplasm (Lukas and Bartek, 2004). Given that this thesis 
work is mainly focused in the ATR/CHK1 pathway, CHK1 function is explained in 
greater detail in the following paragraphs.  
ATR was described as the mammalian equivalent to the main yeast 
checkpoint regulator MEC1p (Cimprich et al., 1996). ATR has several substrates, 
among which CHK1 plays a central role (Matsuoka et al., 2007). CHK1 is 
responsible for spreading the DDR signal throughout the nucleus by regulating 
CDKs activity via CDC25A (Smits et al., 2006). Moreover ATR and CHK1 absences 
have a similar phenotype: embryonic lethality due to massive RS accumulation 
(Brown and Baltimore, 2000; Liu et al., 2000). Thus, the ATR/CHK1 axis is 
essential even at the cellular level.  
CHK1 is the main DDR effector of the G2/M checkpoint. However, it also has 
many other functions. For instance, CHK1 an essential activator of homologous 
repair (Syljuåsen et al., 2005) and it is required for the proper control of the 
mitotic spindle checkpoint (Zachos and Gillespie, 2007), among others. 
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As stated above, CHK1 activation is ATR dependent. Nevertheless, a protein 
called Claspin, that facilitates ATR binding to CHK1, is also required for CHK1 
activation (Kumagai et al., 2006). Claspin levels are tightly regulated through the 
cell cycle, which restricts CHK1 activity to S/G2 phases of the cell cycle (Mailand et 
al., 2006). In addition to Claspin, several complexes take part in the CHK1 
activation process: ATR-ATRIP, Rad17/RFC and the 9-1-1 complex need to be 
recruited to the damaged site in order to induce the activation of CHK1 by ATR 
(Zou et al., 2002).  
CHK1 is required for the establishment of every cell cycle checkpoint in 
vertebrates (Bartek et al., 2007). In addition, there are also evidences of its role in 
the control of replication progression (Syljuåsen et al., 2005). This makes CHK1 
essential during embryogenesis, when most of the cells are undergoing active 
replication (Sørensen et al., 2003). In fact, CHK1 complete deletion renders 
embryonic lethal mice (3.5 embryonic days).  
In addition to knockouts, a mouse strain carrying one extra allele of CHK1 
(CHK1Tg) was recently generated in our laboratory. The insertion of a third CHK1 
copy was able to partially rescue the phenotypes of ATR-Seckel mice. In contrast to 
this, the extra copy did not affect the phenotypes linked to a deficiency in DSBs 
repair (López-Contreras et al., 2012). Moreover, CHK1Tg MEF were found to be 
resistant to various sources of RS, including oncogenes, which facilitated in vitro 
transformation with RAS/E1A oncogene. 
6. Consequences of the DDR 
The main function of ATM and ATR is to coordinate the response to DNA 
damage in cell cycle progression. They avoid that cells keep proliferating with 
damaged DNA with the resulting transmition of mutations to their daughter cells. 
Thus, cell cycle transitory arrest allows the repair of DNA damage. Depending on 
the tissue, and if damage is excessive, the DDR can activate a permanent stop of the 
cell cycle – senescence- or cell death –apoptosis-. Moreover, recent works have 
also described that the DDR can activate differentiation (Inomata et al., 2009).  
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Figure 4. Effects of the activation of the DDR. Once the lesion is detected, the DDR activation 
results in multiple effects: cell cycle arrest in a transitory way through checkpoints or in an 
irreversible manner by the onset of senescence, effects in transcription, cellular differentiation and 
in the activation of repair mechanisms. Depending on the type and amount of damage it can lead to 
apoptosis. Modified from (Hanahan and Weinberg, 2000). 
6.1. Repair 
The cell has two main pathways to repair chromosome breaks: Non 
Homologous End Joining (NHEJ) and Homologous Recombination (HR) 
(Hoeijmakers, 2001). NHEJ is essential for DSB repair during G1. However, it tends 
to introduce mistakes in the DNA sequence. This is because NHEJ binds the two 
ends of the break, at the expense of causing possible local microdeletions. HR is not 
error prone, but it can only take place during S and G2, when there exists a 
homologous chromatid for recombination.  
During NHEJ, break ends are detected by the Ku70/80 heterodimer, which 
then recruits DNA-PKcs. After this, the break is repaired by a complex formed by  
DNA ligase IV and XRCC4 (Hefferin and Tomkinson, 2005). Despite its low fidelity, 
this pathway is able to act in a very urgent way and it can be used in any part of the 
cell cycle. 
 However, when the cell is in S or G2 it preferentially uses the HR, which is a 
high fidelity repair mechanism. The expression of the different components of this 
pathway is restricted to S and G2 phases because HR activity during G1 could 
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result in deleterious consequences, like loss of heterozygosity (LOH) or 
chromosomal translocations (Richardson and Jasin, 2000). The first step of the HR 
pathway involves seeking homologous regions in the sister chromatid. To this aim, 
ssDNA must be generated by DSB resection. Long ssDNA with 3’ ends are 
generated thanks to the action of different helicases and exonucleases (Hiom, 
2000).  After resection, ssDNA is coated with RPA, that will later be substituted by 
another protein with invasive properties: Rad51 (Benson et al., 1994) in a process 
that is facilitated by Rad52. At this point, ssDNA coated with Rad51 invades double 
stranded DNA, displacing the two complementary strands. Next, the replication 
machinery fills the lacking sequence using ssDNA ends as primers. This way, a 
structure called Holyday junction is formed (Bzymek et al., 2010). This structure 
will later give rise to two separated sister chromatids by a mechanism that is 
under debate. There are two possible mechanisms in which this can happen: On 
the one hand, Mus81, Gen1 and SLX4 endonucleases can make breaks to resolve 
the recombination intermediates (Constantinou et al., 2002; Svendsen and Harper, 
2010; Wu and Hickson, 2003). On the other hand, BLM (Bloom Syndrome) helicase 
together with TopIII topoisomerase are able to dissolve these intermediates 
generating only DNA nicks in one of the strands (Wu and Hickson, 2003). Not all 
the components of the pathway or their mechanisms of action are known. 
However, what is certain is that these intermediates are highly recombinogenic 
structures that suppose a threat for the cells. If cells proceed to mitosis before 
repairing these structures, these links between sister chromatids may lead to 
chromosome breaks and asymmetric segregation.  
Defects in repair pathways cause serious diseases. Programmed physiological 
breaks, essential to lymphocytes’ V(D)J recombination and class switching 
recombination (CSR), are repaired via NHEJ. Therefore, the absence of NHEJ 
factors gives rise to a severe immunodeficiency. Moreover, some of the factors 
implicated in HR are of extreme importance in human tumor suppression. For 
instance, BRCA1 and BRCA2, which are frequently mutated in familiar breast and 
ovarian tumors,  are fundamental to recruit Rad51 and their absence seriously 
compromises HR (Welcsh et al., 2000).  
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Figure 5. DSBs repair. Different types of damage can generate DSBs, which are repaired through 
different cellular mechanisms. The most simple repair mechanism, although not always the most 
reliable one, is NHEJ (B). DSBs can also be repaired through HR, that involves the recognition of 
sister chromatids (A). Fundamental steps of each route are represented. 
6.2. Cell cycle checkpoints 
The cell cycle is a sequence of events divided in different phases that are 
separated by transitions under a very strict control. Two of these phases are 
fundamental: the DNA synthesis phase - or S -, and mitosis -or M phase-. DNA is 
replicated during S phase and chromosomal segregation and division of the two 
daughter cells take place during M phase.  In between these two phases we find 
G1–after M - and G2–after S phase-. During G1 and G phases cells get ready for the 
essential parts of the cell cycle. When no continuous proliferation is required, cells 
enter in a quiescent state that is called G0. Complex control mechanisms ensure the 
generation of a single and exact copy of genetic material and its equal distribution 
between the two daughter cells.  Cells cannot enter a new phase until they meet all 
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the requirements that define the end of the previous one. The precise and tidy 
progression through the cell cycle is granted by the sequential activation of Cyclin 
dependent kinases (CDKs) (Morgan, 1997). Each of the cell cycle checkpoints will 
be reviewed in greater detail in the next section (B) of this introduction. 
6.3. Senescence and apoptosis 
Senescence was described over 50 year ago in human cells (HAYFLICK, 
1965). They observed that human fibroblasts in serial culture entered an 
irreversible cell cycle arrest after 50-70 divisions. Later on, p53 was proven to 
mediate in this type of arrest together with the p16INK4a/RB axis (Kuilman et al., 
2010). Nowadays, senescence is considered a stress response implicated in cancer 
protection and ageing (Collado et al., 2007). One of the causes of this permanent 
cell cycle arrest is telomere shortening. Dysfunctional telomeres are recognized as 
DSBs and are able to trigger the DDR (d'Adda di Fagagna et al., 2003). Other forms 
of permanent damage that can induce premature senescence include oxidate stress 
in culture (Parrinello et al., 2003) and genotoxic agents (Campisi and d'Adda di 
Fagagna, 2007). Later it was discovered that oncogene activation could also lead to 
an irreversible and premature stop, similar to proliferation induced senescence, in 
vitro (Serrano et al., 1997). This arrest is activated by p53 and mediated through 
p19ARF.  Today we know that senescence also appears in human and murine 
tumors (Collado and Serrano, 2005). Consistently, some oncogenes, like RAS, 
CDC6, STAT5 or Cycline E trigger a DDR associated to DNA hiperreplication, which 
finally activates senescence (Bartkova et al., 2006; Di Micco et al., 2006). Finally, it 
has been proven that the activation of ATR is able to promote senescence even in 
the absence of damage (Toledo et al., 2008).  
 Apoptosis is a death mechanism actively executed by the cell. It is 
determined by the sensitivity of each particular cell type and by the intensity of the 
DDR, which is proportional to the number and severity of the lesions. When a 
certain amount of damage is reached, p53 is activated by the DDR and it induces 
the expression of genes implicated in cellular death, like Puma, Noxa and Bax 
(Nakano and Vousden, 2001). These genes cooperate in mitochondrial membrane 
permeabilization and cytochrome C release into the cytosol (Willis et al., 2007). All 
these events lead to the formation of a proapoptotic protein complex until finally, 
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caspase enzymes are activated. Caspases inactivate proteins that protect living 
cells from apoptosis, directly disassemble and degrade cell structures such us DNA, 
conducting to cell death.  
Why certain cell types undergo apoptosis and other senescence in response 
to DNA damage is still a matter of debate (Campisi, 2007). For instance, whereas 
DNA damage in fibroblasts promotes senescence, low amounts of DNA breaks in 
lymphocytes are able to activate apoptosis.  
6.4. Differentiation 
Different genomic instability mouse models have showm a decrease in stem 
cell population (Murga et al., 2009; Ruzankina et al., 2007). This effect was 
considered to be due to the main effects of the DDR: senescence and apoptosis 
(Ruzankina et al., 2008). However, an in vivo study of the effects of the DDR in 
melanocytes unveiled that activation of the DDR can also lead to stem cell 
differentiation (Inomata et al., 2009). This differentiation implies a decrease in the 
stem cell pool and entails hair graying in animals.  Hence, the DDR maintains the  
good quality of  the stem cell pool through the differentiation of damaged stem 
cells. 
7. Biological implications of the DDR 
7.1. DDR and ageing 
Ageing can be accelerated by different DDR-activating stimuli like telomere 
shortening, oxidative stress, genotoxic agents or replication stress. Being this last 
one the least understood cause. As mentioned, replication stress refers to any 
problem that might happen in the replication fork and that implies the 
accumulation of long ssDNA strands or even DSBs (López-Contreras and 
Fernandez-Capetillo, 2010). Moreover, aged tissues and stem cells show an active 
DDR (Rossi et al., 2007). Thus, DNA damage accumulation has been related to 
senescence and ageing (Garinis et al., 2008).  
The relationship of ATR with aging barrier is still not well understood. Partial 
ATR loss is known to generate a progeroid phenotype (Murga et al., 2009) 
associated to high RS levels during embryonic stage. An interesting hypothesis is 
that the conditions during embryonic development have an important effect in the 
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life’s expectancy of the adult organism (Fernandez-Capetillo, 2010). In addition, 
full ATR loss in adult tissues leads to the elimination of cells and the faster 
mobilization of stem cell pools, with the consequent development of ageing 
phenotypes (Ruzankina et al., 2007). Nevertheless, both hypotheses point towards 
a relationship between RS and ageing. At the cellular level, both the loss of ATR 
(Murga et al., 2009) or its activation (Toledo et al., 2008) lead to senescence. All of 
the above suggest a connection between ATR, RS and ageing. 
7.2. DDR and cancer 
One of the main hallmarks of a cancer cell is the development of genomic 
instability, which generates random mutations including chromosomal 
rearrangements. Eventually, some genetic changes might be able to promote 
cellular transformation (Hanahan and Weinberg, 2011). Also, the two main 
classical strategies for cancer treatment, chemotherapy and radiation, are based on 
the generation of DNA damage (Toledo et al., 2011a). When exposed to radiation 
or chemotherapy, both cancer and healthy cells will incorporate some damage in 
their DNA. However, cancer cells are particularly sensitive to DNA damage 
inducing agents due to their faster replication rates. 
In this context, the relationship between the DDR and DNA repair with tumor 
development has been deeply investigated. On the one hand, the DDR has been 
proposed as an anticancer barrier in the first steps of tumor development 
(Halazonetis et al., 2008). During these initial stages oncogenes would promote 
uncontrolled proliferation; leading to RS, which will activate the DDR machinery 
(Bartkova et al., 2005; Gorgoulis et al., 2005).  On the other hand, defects in HR and 
NHEJ lead to the accumulation of chromosomal aberrations. In fact, most human 
syndromes associated to defects in the signaling or repair of DNA damage are 
characterized by the appearance of cancer. Many of these syndromes have been 
reproduced in murine models. Sometimes, the loss of only one allele is sufficient to 
drive tumorogenesis, which classifies these genes as haploinsufficient tumor 
suppressors. ATR and CHK1 are both haploinsufficient genes, given than mice with 
a single ATR or CHK1 allele are prone to tumor development (Brown and 
Baltimore, 2000; Liu et al., 2000). This phenotype is seriously aggravated in a 
genetic background with other mutations that are also procancerous (Lam et al., 
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2004). Paradoxically, even though ATR or CHK1 loss predisposes to cancer onset, 
CHK1 inhibitors have been proposed as a cancer treatment (Tao and Lin, 2006). 
This apparent contradiction can be explained analyzing CHK1 levels: whereas half 
of CHK1 predisposes to the accumulation of mutations and, therefore, tumor 
development, the complete inhibition of CHK1 is too toxic for replicating cells. For 
instance,  CHK1 inhibition is especially toxic for p53 null cells, which accumulate 
higher levels of RS (Koniaras et al., 2001). This is of particular interest, since p53 is 
one of the most frequently mutated tumor suppressors in human cancer, and p53 
deficient tumors are very often resistant to the available therapy. In agreement 
with this model, mice with low ATR levels do not develop cancer. Moreover, p53 
elimination in this model not only does no lead to tumor development, but is 
extremely synthetic lethal (Murga et al., 2009; Ruzankina et al., 2007). This is the 
basis for a personalized use of ATR or CHK1 inhibitors, through directing their use 
to tumors with high levels of RS. This phenomenon is due to the role of CHK1 in 
suppressing RS, so that ATR or CHK1 inhibitors are particularly toxic for cells 
suffering from RS. 
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B. The cell cycle 
The transitions through the different stages of the cell cycle are strongly 
regulated by the activity of Cyclin-dependent kinases (CDKs). CDKs are activated 
by Cyclins and inhibited by CDK inhibitors (CKIs) or inhibitory tyrosine 
phosphorylations (Guardavaccaro and Pagano, 2006). Briefly, four main CDKs are 
involved in the regulation of cell cycle; CDK2, CDK4 and CDK6 during interphase, 
and CDK1 during mitosis. When the DDR is activated, it can limit the activity of 
CDKs and therefore, prevent the progression of the cell cycle into the next phase 
(G1/S and G2/M checkpoints). Additionally, the DDR can also slow down 
replication (intra-S checkpoint), although this is not a full stop and cells progress 
with damage from S into G2 phase and finally stop at the G2/M checkpoint 
(Abraham, 2001).  
1. Cell cycle checkpoints 
The DDR reaches the CDKs through effectors that limit CDK activity: First, the 
main proteins from the DDR network that regulate checkpoints are the checkpoint 
kinases CHK1 and CHK2, direct substrates of ATR and ATM correspondingly 
(Bartek and Lukas, 2003). Checkpoint kinases act by regulating CDK inhibitory 
effectors such as Cdc25a, Wee1 or p53. Cdc25a is a phosphatase that controls 
CDK1 and CDK2 activities. In response to DNA damage, CHK1 phosphorylates 
Cdc25a inducing its degradation (Liu et al., 2000), and thus, inhibition of CDK 
activity (Boutros et al., 2006). Finally, a key mediator of cellular responses to DNA 
damage is p53. p53 is quickly stabilized upon DNA damage by a range of post 
translational modifications. ATM, ATR, CHK1 and CHK2 are all able to 
phosphorylate p53 contributing to its stabilization (Canman et al., 1998). Besides 
its apoptotic targets, p53 has several transcriptional targets that contribute to 
checkpoint onset, the most known being p21 (CDKN2A), a central regulator of the 
G1/S checkpoint.  
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1.1. G1/S Checkpoint 
To avoid that a damaged cell enters S phase, the DDR can stop the cell cycle 
by two main effectors that function in parallel: CDC25A and p53 (Lukas and 
Bartek, 2004). Although phosphorylation of both substrates happens 
simultaneously, the cascade triggered by CDC25A is faster. This is because it does 
not require new protein synthesis (Mailand et al., 2000). Nevertheless, full 
checkpoint implementation is carried out by p53 accumulation. In response to 
DNA damage, CDC25A is phosphorylated. CDC25A phosphorylation marks the 
protein for its degradation in the proteasome, what avoids that CDC25A 
dephosphorylates and activates CDK2. The slower response implies p53 activation 
and stabilization. This happens through several mechanisms, such as p53 
phosphorylation in its serine 15 by ATM (Tibbetts et al., 1999) and in its serine 20 
and treonine 18 by CHK2 (Hirao et al., 2000; Shieh et al., 1997).  Moreover, ATM 
interacts with the negative regulator of p53, MDM2 (Shieh et al., 1997) . Finally, 
p53 can also be acetylated (Dornan et al., 2003), what increases p53 
transactivation potential in response to DNA damage (Dumaz and Meek, 1999).  
One of the transcriptional targets of p53 is p21, which is accumulated hours after 
the detection of damage. p21 inhibits G1-S transition by limiting  to Cyclin E/CDK2 
(Sherr and Roberts, 1999). 
1.2. Intra-S Checkpoint 
This checkpoint consists in a transitory delay in cell cycle progression 
(Abraham, 2001) through the prevention of replication origin firing. This is 
achieved by CDC25 degradation, after its phosphorylation by ATR/CHK1 and CDK2 
inhibition (Bartek et al., 2004). SMC1 phosphorylation by ATM has also been 
suggested as an activator of the intra-S checkpoint (Kitagawa et al., 2004). The 
intra-S checkpoint helps stabilizating replication forks through a not yet elucidated 
mechanism. Through the activation of this checkpoint cells avoid replication fork 
collapse and the consequent DSBs that arise from it (Bartek et al., 2004).  
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1.3. G2/M Checkpoint 
G2 arrest avoids the entrance in mitosis of cells that present DNA damage. 
The main target of this checkpoint is Cyclin B/CDK1. DDR phosphorylation of 
CDC25A by CHK1 and CHK2 avoids Cyclin B/CDK1 activation (Donzelli and 
Draetta, 2003). Once again, the p53/p21 axis is in charge of the maintenance of this 
checkpoint (Taylor and Stark, 2001). The DDR activates this checkpoint mostly 
through ATR/CHK1, although ATM/CHK2 can also participate in the G2/M 
checkpoint. 
 
Figure 6. Checkpoints in the DDR. Representation of the transitory control of the cell cycle by 
ATM and ATR kinases. During G1 phase cell cycle arrest is activated by ATM/CHK2 kinase. On the 
other hand, during G2 phase ATM activates the ATR/CHK1 pathway.    
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2. Relevant cell cycle regulators  
The advance through the different stages of the cell cycle is very tightly 
regulated by CDKs and CDKis (Guardavaccaro and Pagano, 2006). There are 
different effectors that can regulate CDK activity. In the following pages I will 
describe in more detail some of these regulators that are of special interest for this 
thesis. 
2.1. Retinoblastoma 
Retinoblastoma was the first tumor suppressor cloned, now more than 25 
year ago. It controls whether the cell is prepared to initiate DNA replication and 
divide (Classon and Harlow, 2002). RB elimination promotes uncontrolled 
proliferation and tumor development.  
The first studies of RB focused on its function at the G1-S transition, where it 
inhibits E2F. This perspective offered a clear explanation of RB tumor suppressor 
function (Hatakeyama and Weinberg, 1995). Different from most cell cycle 
proteins, RB is not usually degraded upon inactivation. On the contrary, RB 
persists until mitosis, when it is dephosphorylated in order to allow the start of a 
new ell cycle (Kolupaeva and Janssens, 2013). RB presence during the whole cell 
cycle allows its reactivation by dephosphorylation in response to intra S or G2/M 
checkpoints. In addition to this, new studies show that other post-transcriptional 
modifications, such us acetylation or methylation, can also modulate RB activity 
(Munro et al., 2012).  
Human RB has three main domains: a central –pocket- domain flanked by 
two linker sequences than bind an amino-terminal domain and a carboxi-terminal 
one (Dick and Rubin, 2013). The pocket domain is highly conserved; it binds E2F 
and viral oncoproteins. The linker sequences contain CDK-dependent 
phosphorylation sites that have a critical role for RB regulation (Burke et al., 
2012).  
The vast majority of human sporadic cancers carry mutations in RB or in its 
pathway. Some of these mutations affect RB regulators suchs us Cyclin D, CDK4 or 
p16INK4a (Sherr, 1996). RB knock- out mice are embryonic lethal; they die at mid-
gestation (E. 12-15) due to neurogenesis, erythropoyesis and lens development 
defects (Vooijs and Berns, 1999). RB heterozygous mice develop tumors in which 
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the RB wildtype (WT) allele is lost.   Moreover, many models of tissue specific 
deletion of RB have been shown to lead to cancer, particularly when combined 
with p53 deletion (Vooijs and Berns, 1999). 
RB can be inhibited by some proteins of viral origin (DeCaprio et al., 1988) 
such us the large T antigen of the simian virus 40. DNA viruses can code for a 
variety of oncoproteins with no cellular homolog. Polyomaviruses are a type of 
DNA virus that can cause different type of diseases in animals. Among them, SV40 
is a polyomavirus from rhesus macaque (Macaca mulata) origin than contains two 
coding regions. In the first one, it contains two proteins: Large-T antigen and small-
t antigen (White and Khalili, 2006). Large-T antigen is able to regulate important 
cellular signaling pathways to boost cell cycle progression. As a result of this 
enhance in proliferation, virus-infected cells transform. In fact, the Large-T antigen 
is able to interfere with the functions of the two main tumor suppressors: p53 
(Lane and Crawford, 1979) and RB (DeCaprio et al., 1988) among many other 
proteins. It preferentially binds to hypophosphorylated RB (Ludlow et al., 1989), 
displacing E2F (Chittenden et al., 1991). Different forms of the SV40 Large-T 
antigen have been used to study RB and p53 roles and to immortalize culture cells. 
A mutant T-antigen composed of only the 121 N-terminal aminoacids retains the 
capacity to interact with RB but not p53 (Figure 7). This small version of the T-
large antigen, called T-121, is able to avoid the inhibition of growth by cell contact 
(Tevethia et al., 1997b), to immortalize cells in vitro and to cause tumors in vivo 
(Tevethia et al., 1997a). Of note, T121 also binds to p107 and p130, the two other 
proteins of the Retinoblastoma family, together with RB (Stubdal et al., 1996), that 
also contribute to the regulation of the cell cycle in certain tissues. 
Figure 7. T-Large antigen 
domain structure Protein 
domains of the T-Large 
antigen (blue) and   their 
corresponding aminoacids 
are indicated. Note the Rb-
protein binding region 
(LXCXE) and the ATPase 
region containing the p53 binding site (ATPase). RB and p53 are depicted in orange with their 
corresponding interactions with T antigen (red dots). Modified from (Sáenz Robles and Pipas, 
2009) 
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2.2. INK4a/ARF 
The INK4 locus was extensively studied at the end of last century. Two 
different research lines claimed a new tumor suppressor gene in chromosome 9, 
which was named p16INK4a. Later on, homologs of the gene were found at the same 
locus and designated p15INK4b (Quelle et al., 1995a), p18INK4c (Guan et al., 1994)and 
p19INK4d (Guan et al., 1996). Later, an alternative transcript from the INK4a locus 
was found. p16INK4a is composed by three exons: INK4a-1, INK4-2 and INK4-3. 
The alternative transcript starts with exon INK4a1, which is transcribed from a 
different promoter than exon INK4a-1. Then, exon INK4a1 becomes spliced to 
the same second and third exons INK4-2 and INK4-3. Altogether,  exon INK4a1, 
INK4-2 and INK4-3  form an alternative transcript named p14ARF in human or 
p19ARF in mouse (Mao et al., 1995). 
p16INK4a inhibits the kinase activities of CDK4 and CDK6. They directly bind to 
CDK4 and CDK6, acting as competitive inhibitors and preventing the association of 
CDKs with the corresponding Cyclin. Therefore p16Inka4 overexpression leads to a 
G1 arrest (Guan et al., 1996; Hirai et al., 1995; Serrano et al., 1993).  p16INK4a 
expression in primary tissues is generally low or undetectable. However, it is more 
easily detected in cells in culture. For instance, p16INK4a expression could not be 
detected in mouse embryos, but its transcription was activated the moment 
embryonic fibroblasts were cultivated (Zindy et al., 1997). This fact suggested that 
p16INK4a could be part of the mechanism that limits the lifespan of proliferative 
cells, namely proliferation-induced senescence (HAYFLICK, 1965). Further 
evidence came with the demonstration that p16INK4a accumulates with increasing 
numbers of population doublings (Hara et al., 1996). Apart from proliferation-
induced senescence, there is another scenario in which p16INK4a levels are 
increased: a RB depleted background. The excess of p16INK4a in RB negative cells 
was already reported in the original publication by Serrano et al. (Serrano et al., 
1993). Nullizigous mice for p16INK4a show certain tumor susceptibility and 
carcinogen hypersensitivity. Moreover embryo fibroblasts (MEF) derived from 
them show an increase rate of immortalization compared to wildtype, but they 
proliferate normally and undergo proliferative senescence (Krimpenfort et al., 
2001; Sharpless et al., 2001). Thus, p19ARF could be compensating the lack of 
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p16INK4a in MEFs,  what suggests a predominant role for p19ARF over p16INK4a in this 
murine cell type (Sharpless et al., 2004). 
In contrast to p16INK4a, p19ARF is widely expressed in primary tissues and it 
does not bind to CDKs, although its ectopic expression does lead to cell cycle arrest 
(Quelle et al., 1995b). The effects of p19ARF are dependent on p53 status and lead 
to both G1 and G2 phase arrest (Kamijo et al., 1997). p19ARF appears to protect p53 
from degradation by directly binding MDM2 (Pomerantz et al., 1998). Accordingly, 
p19ARF levels are higher in p53-negative cells (Kamijo et al., 1997). Nullizigus mice 
for p19ARF develop spontaneous tumors, are susceptible to chemical carcinogens 
and their fibroblasts bypass proliferative senescence (Kamijo et al., 1997). Hence, 
and in contrast to the human situation, p19ARF seems to be the key tumor 
suppressor at the INK4a/ARF locus in mice. 
 
Figure 9. The INK4a/ARF locus and 
CC regulation. The INK4a/ARF locus 
encodes p16INK4a and its relatives, as 
well as p19ARF. The genetic locus is 
depicted as a grey line with exons 
indicated by colored boxes (green for 
p16INK4a and yellow for p19ARF). 
p16INK4a is a member of the Cyclin 
dependent kinase inhibitors that binds 
to inactive CDK4/6, resulting in RB 
indirect activation. p19ARF inhibits 
MDM2, resulting in p53 stabilization. 
Modified from (Kim and Sharpless, 
2006). 
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Not long after its discovery, the locus encoding p16INK4a was found to be 
mutated in a wide range of cancer types (Kamb et al., 1994). Nevertheless, the 
locus also encodes p19ARF, which is an activator of p53. Altogether, this makes the 
INK4a/ARF locus a key player in cancer, since it can activate the two main tumor 
suppressor pathways in our cells: p16INK4a/RB and p19ARF/p53. In human cells, 
however, p16INK4a seems to be the main contributor to tumor suppression. 
Moreover, cancer-associated mutations imply either the entire locus, or p16INK4a 
alone (Quelle et al., 1995b). The relevance of the whole INK4a/ARF locus is 
evidenced by its frequent loss in human cancer (Sherr, 2012). Deletion of the 
whole INK4a/ARF locus renders viable, but highly tumor prone mice that are very 
sensitive to carcinogenic treatments. INK4a/ARF depleted MEF proliferate rapidly 
and bypass proliferation induced senescence (Serrano et al., 1996). Nevertheless, 
p16INK4a is considered the main contributor of the locus to tumor suppression in 
humans (Kim and Sharpless, 2006). In fact, it has been found to have alterations in 
a wide variety of human cancers (Table 1) (Ruas and Peters, 1998). 
 
Table 1. The table represents the 
percentage of tumors that have 
sustained either homozygous 
deletions or mutations 
Abbreviations are used as follows: 
ALL, acute lymphoblastic leukemia; 
ATL Adult T-cell leukemia; NHL, 
Non-Hodgkin’s lymphoma; CML, 
chronic myeloid leukemia; SCC, 
squamous cell carcinoma; TCC, 
transitorial cell carcinoma; NSCLC, 
non-small cell lung cancer; NPC, 
nasopharyngeal carcinoma. Only 
the most representative cases are 
depicted. Modified from (Ruas and 
Peters, 1998). 
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One of the cancer types in which p16INK4a is frequently mutated is melanoma. 
It is widely known that exposure to UV radiation increases the risk of melanoma 
due to the induction of DNA damage. Together, these two facts suggest an 
important role for p16INK4a in the response to the DNA damage induced by UV 
radiation. In fact, the depletion of p16INK4a, p19ARF or the whole locus has been 
proven to cause a defect in the repair of DNA damaged with UV radiation (Sarkar-
Agrawal et al., 2004). Moreover, p16INK4a null cells are hypersensitive to UV 
radiation (Al-Mohanna et al., 2004). Finally, p16INK4a has been shown to stabilize 
p21 and induce p53 in response to the exposure to UV radiation (Al-Mohanna et 
al., 2007). However, several studies failed to show a role for p16INK4a or p19ARF in 
the acute response to ionizing radiation (Efeyan et al., 2006; Kamijo et al., 1999), 
which suggested that this locus was not linked to the DDR. 
2.3. p53 
p53 is probably the most important tumor suppressor in pluricelullar 
organisms. In addition, it is the main regulator in the response to different cellular 
insults such us DNA damage. p53 is considered to prevent tumor onset by 
executing the effects of the DDR, and it is present in premalignant and malignant 
cells (Bartkova et al., 2005; Gorgoulis et al., 2005). DNA Damage was the first type 
of cellular insult associated to p53; this was the reason David Lane called this 
tumor suppressor “the guardian of the genome” over twenty years ago (Lane, 
1992). p53 response to DNA damage has been deeply investigated; DNA damage 
activates the DDR proteins ATM, ATR, CHK1 and CHK2, which phosphorylate p53 
(Chao et al., 2000; Kurz and Lees-Miller, 2004). This signaling cascade is 
hiperactivated in human tumors, suggesting that cancer and DNA Damage are 
intrinsically associated (Bartkova et al., 2005; Gorgoulis et al., 2005).  
Oncogenes are also able to activate p53 (Serrano et al., 1997) through p19ARF. 
p19ARF inhibits the degradation of p53, allowing p53 activation. Once it has been 
activated, p53 triggers a transcriptional program that results in different types of 
cellular responses that vary depending on the cellular type and the degree and 
duration of the activation. In the end, p53 activation will lead to cell cycle arrest, 
mainly through p21 regulation, and to apoptosis through the activation of genes 
such us Puma, Noxa or Bax. 
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The   great   importance   of   p53   in   cancer   has   been  widely  proven.  p53 
nullizigous mice show a high cancer predisposition (Donehower et al., 1992; Jacks 
et al., 1994).
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OBJECTIVES 
 
1. To investigate the potential role of the INK4a/ARF and RB pathways in the 
onset of replication stress induced senescence. 
 
a. To explore if the INK4a/ARF locus is activated in response to 
replication stress. 
 
b. To investigate whether the products of the INK4a/ARF locus; 
p16INK4a and p19ARF, regulate cell cycle arrest in response to 
replication stress. 
 
c. To investigate whether the inactivation of the RB pathway allows the 
growth of cells with replication stress.  
 
2. To investigate the impact of INK4a/ARF mutations in the context of reduced 
ATR activity. 
 
a. To study how INK4a/ARF deletion affects the symptoms of ATR-
Seckel Syndrome in mice. 
 
b. To investigate whether the sensitivity of tumoral cells to ATR 
inhibitors is dependent on the status of the INK4a/ARF locus. 
 
3. To explore whether the cell lethality of ATR deficient cells can be rescued 
by the inactivation of RB proteins. 
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MATERIALS AND METHODS 
1. Mice 
1.1. Maintenance and genotyping of mice  
All animals used during the development of this thesis were kept in the 
Animal facility of the Spanish National Cancer Research Center, according 
with Spanish animal protection law (RD1201/2005) and the European 
directive (86/609/CEE) established to regulate the standards of animal care.  
In order to genotype the animals, DNA was extracted from small tail 
pieces that were digested during 12 hours at 55°C with the following lysis 
buffer: NaCl 100 mM, Tris-HCl pH 8 20 mM, EDTA10 mM, SDS 0.5% and 
proteinase K (Roche) 400 μg/ml. Cellular lysates were treated with a 
saturated NaCl solution and DNA was precipitated with isopropanol, washed 
with ethanol and resuspended in distillated water.  
PCRs of this work were performed according to these two protocols:  
A)  In a 10 μl final volume reaction: 200 μM de dNTPs, 1.5 mM de 
MgCl2, 1 μl reaction buffer 10X, 0.15 μl Taq polymerase (Platinum Taq, 
Invitrogen), 0,5 μM of each oligonucleotide and 100 ng of genomic DNA.  
B) In a 10 μl final volume reaction: 200 μM de dNTPs, 1.5 mM de MgCl2, 
5 μl reaction buffer 2x (MasterAmp, Buffer F) 10X, 0.15 μl Taq polymerase 
(Platinum Taq, Invitrogen), 0,5 μM of each oligonucleotide and 100 ng of 
genomic DNA. 
1.1.1. ATR Seckel 
The oligonucleotides used amplify a region close to the vector’s site of 
integration. They amplify a band of 500bp in the wild type allele or 300bp in 
the knocked in one. The PCR was performed according to protocol A, and the 
sequences of the oligonucleotides are:  
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Seckel 3’E8: GGAATAAATCCATGGAAGTGAGAGCAT  
Seckel neo: TCCTCGTGCTTTACGGTATCGCC  
Seckel 5’In7-8: CACTGGCCTCACAGACTTCAGCATG 
1.1.2. INK4a/ARF KO and p16INK4a KO 
INK4a/ARF KO and INK4a KO alleles were genotyped by Transnetyx 
(Transnetyx, Inc). 
1.1.3. p19ARF KO 
Two separate reactions were used to genotype ARF mutant mice. The 
nucleotides used to amplify the wild type (ARF1bis and ARF2) allele render a 
457 bp band. The mutant allele maintains a neomycin site, when amplified 
with the chosen oligonucleotides (Neo-2 and ARF2) it gives a 250 bp band. 
The PCR was performed according to protocol B, and the nucleotides are:  
 ARF1 bis:  TCTCACCTCGCTTGTCACAGTG 
 ARF2:   TTGAGGAGGACCGTGAAGCCG 
 Neo-2:  ACCACACTGCTCGACATTGGG 
1.1.4. RB lox/lox UbCreERT-2 
RB conditional knock out mice were genotyped with a single reaction. 
The nucleotides amplify a 680bp band in the case of a wild type allele, 750bp 
band in the case of the allele had integrated two lox sites and a 300bp in the 
knock out one. The PCR was performed according to protocol B, and the 
nucleotides are: 
 pRB18 Rev:  GGCGTGTGCCATCAATG 
 pRB19 Fwd: AACTCAAGGGAGACCTG 
Cre recombinase was amplified following PCR protocol A. The 
nucleotides chosen render a band of 400bp: 
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 Cre1:  CGATGCAACGAGTGATGAGGTTC 
 Cre2:  GCACGTTCACCGGCATCAAC 
1.2. Survival curve 
At least 15 mice (male and female) from every genotype of interest 
were maintained for each survival analysis. Age and possible cause of death 
were annotated. Survival times were analyzed with GraphPrism and a 
Mantel-Cox test was performed in order to find out whether differences are 
statically significative. 
1.3. Immunohistochemistry 
Tissue samples and embryos were embedded in formalin to their later 
process at CNIO’s Pathology Unit. 2,5mm tissue sections were treated with 
citrate and stained with the antibody of interest. Hematoxilin and Eosin were 
used to counterstain.  
1.4. Body imaging analysis – Densitometry 
Densitometry measurements were performed by CNIO’s Imaging Unit, 
where they use DEXA equipment from GE. Pictures were analysed by PixiMus 
DeXa system from GE  and a high resolution software that allows the 
stimation of bone density as well as fat accumulation. To perform these 
measurements animals were anesthesiased using non invasive techniques. 
1.5. T121 conditional mice generation  
Open biosystems gene targeting kit (cat num. MES4758)  was used to 
generate inducible genetically- modified embryonic stem cells (ESC) that 
recombine T121 in a by specific site (Beard et al., 2006). The recombination 
took place in a particular type of ESC, called KH2 that includes a tetracycline-
inducible system, (Urlinger et al., 2000), to regulate gene expression both in 
vitro and in vivo.  
In brief, T121 was cloned in a pBS31 vector, which allows T121 
introduction downstream of the tetO minimal CMV promoter. Sequencing 
was used to confirm the integrity of the construction that was later 
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electroporated in KH2 ESC by CNIO’s transgenic’s Unit personnell. In the 
presence of FLPe recombinase pBS31 will insert T121 genomic sequence at 
the frt site along with a promoter and an ATG initiation codon upstream and 
in frame with the hygromycin resistance gene thereby conferring hygromycin 
resistance to the correctly targeted cell. 
Targeted ESC were selected by hygromycing treatment and the 
integration in different clones was later confirmmed by Southern blot, using 
the probe specified in the kit (Open biosystems; cat num. MES4758).  Last, 
one of the selected clones was microinjeted in mouse morula to generate 
chimeric mice. The electroporation and microinjection were done twice and 
none of the chimeric mice produce were viable or fertile. 
1.5.1. Southern blot 
Aproximately 15ug of DNA were digested with the SpeI (New England 
Biolabs) enzyme for 12h at 37°C in a solution containing digestion buffer 
(NEB Tango) , BSA 0,1mg/ml and espermidine 2,5mM.  Digested material was 
separated by electrophoresis in a 0,8% agarose gel at low voltage during 
enough time to adecuately separate DNA. After this, the gel was incubated in 
a 0,25M HCl solution for 15 minutes in order to denaturalize the DNA. The gel 
was washed with destilated water and treated with a second denaturalizing 
solution containing NaOH 0,4M and 0,6M NaCl. After a second washing the 
gel was immersed in a 0,5M Tris-HCl pH 7,5, 1,5M NaCl neutralizing solution 
during 30 minutes. All treatments were done at room temperature with 
gentle shaking. DNA was transferred by diffusion in SSC10x to a positively 
charged nylon membrane (Hybond XL, Amersham, Buckinghanshire, UK) 
during at least 12 hours. After this, ultraviolet light was used to enhace 
covalent linkage of DNA to the membrane (Stratalinker, Stratagene, Agilent 
Technologies, Santa Clara, CA). Membrane was prehibridated with a 
hibridating solution (0,25m sodic phosphate pH7,2, 1mM EDTA, 1%BSA, 
7%SDS) at 65°C for a minimum of 2hours. During this time radiactive 
labeling of the probe was performed. 20ng of the adequate probe (Open 
biosystems; cat num. MES4758) are dissolved in a final volume of 45ul TE. 
The probe was denaturalized at 99°C and amplified according to the 
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instructions of the Random Prime System (Stratagene) with 50Ci of [32P] 
dCTP and it was purified by filtration in a Sephadex G-50 Column 
(ProbeQuant GE Healthcare).  The DNA that had been transfered to the 
membrane was hibridated to the probe at 65°C overnight in a  hibridating 
solution containing 0,05mg/ml salmon sperm (Invitrogen). Once the 
hibridation was over the membrane was washed in SSC 2x during 10 
minutes, then it was washed again during 30 minutes in a SSC 2x, 1%SDS 
containing solution and finaly during another 15 minutes in SSC 0,2x, 
0,1%SDS. After the washing steps the membrane was exposed in a cassette 
with a PhosphorImager detection screen during the convinient time and it 
was developed with a Typhoon TRIO scaner (GE Healthcare). 
2. Molecular and cell biology 
2.1. Cell biology 
Unless otherwise specified, all cell lines were cultured in DMEM media 
(4.5 g/L Glucose; L- Glutamine) (Lonza, Switzerland) with 10% -20% of 
inactivated fetal bovine serum (FBS) (South American Origin, Lonza) and a 
mix of penicillin and streptomycin (Gibco, Invitrogen, Life Technologies, 
Carlsbad, CA). All cell types used are of murine origin: MEFs, B cells, 
pancreatic carcinoma cell lines, ESC, an iPSCs. They were kept in incubators 
at 37 °C and 5% C02, except for MEFs, that were maintain in hypoxia 
incubators, at 37 °C and 5% C02 and 5%O2. 
2. 1. 1. Production of MEFs (mouse embryonic fibroblasts)   
Female and male mice of the desired genotype were mated until vaginal 
plugs were visible. At 13.5 day of gestation the female was sacrificed and 
embryos were extracted. In sterile conditions, the fetal liver was removed, as 
well as a little piece of head from which DNA was obtained for genotyping. 
The remaining embryo was cut with a sterile blade and incubated 10 minutes 
in 1ml trypsin 0,25%, EDTA (Gibco). The resulting mix was pipetted up and 
down in order to dissolve all aggregates and finally the trypsin was 
neutralized with 9ml DMEM media (4.5 g/L glucose, L-Glutamine (Gibco) 
supplemented with 10 - 15% inactivated (30 minutes at 55°C) fetal bovine 
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serum (FBS) and 1% penicillin/streptomycin (Gibco, Invitrogen, Life 
Technologies, Carlsbad, CA). The total 10ml were transferred to a p100 plate 
that was kept in hypoxia incubators (5% O2). The media was changed the 
following day in order to eliminate dead and blood cells.  
2. 1. 2. Isolation of splenic B lymphocytes      
Splenectomy was performed in mice at age 6 to 10 weeks. Whole 
spleens were squeeze in washing buffer: PBS 1x with 1% bovine seroalbumin 
(BSA Fraction V, Roche). Supernatants were treated with a hypotonic 
solution (ACK Lysing Buffer, Lonza) during 5 minutes, after which the 
solution was inactivated with washing buffer. Cellular aggregates were later 
eliminated with a 40m filter and the lysate was centrifuged 5 minutes at 
350g. Sediment was suspended in 900l of washing solution to which 80l of 
anti-CD19 antibody conjugated magnetic beads Mouse CD19 Micro Beads, 
Miltenyi Biotech, Germany) were added. The mix was incubated at 4°C during 
15minutes. After this time, cells were washed, suspended in 1ml washing 
solution and transfer to a separating column (MS Columns, Miltenyi) standing 
in a magnetic scaffold (OctoMACS separator, Miltenyi). Cells linked to the 
anti-CD19 beads are separated due to their attraction to the magnetic field. 
After washing the column, these cells were eluted outside of the magnetic 
field. Primary B lymphocytes were maintain in culture (1x 106 cells/ml) in 
RPMI media (Euroclone) supplemented with 10% FBS, 
1%penicillin/streptomycin (Gibco, Invitrogen), glutamine 2mM (Gibco, 
Invitrogen), non essential aminoacids (Lonza), sodium pyruvate Gibco, 
Invitrogen), b-mercaptoetanol 50 mM (Gibco, Invitrogen) and HEPES 10 mM 
(Lonza). 25mg/ml LPS (LPS, Sigma-Aldrich, St. Louis, MO) were added to 
stimulate cells. 
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2.1.3. Proliferation curve 
1,25 x 105 MEFs were seeded in a 35mm plate, after 2 days cells were 
counted and 1,25 x105 MEFs were seeded again (3T3 protocol) (Todaro and 
Green, 1963). The increase in population doublings (PDLs) was calculated 
applying the formula PDLs = log ( nf / n0 ) / log2, where n0 is the initial cell 
number and nf is the final cell number in each passage.  
2.1.4. shRNA infections  
For the production or retrovirus, each retroviral vector (T121, 
shINK4a/ARF, shp16INK4a, shp19ARF, shp53, shpRB, shpBabe) was 
cotransfected in 293T cells with the retrovirus packaging vector pCL-ECO 
(ratio1.5:1). The transfection vehicle was lipofectamine 2000 (Invitrogen). 48 
hours after the transfection, the viral containing supernatants were collected, 
filtered and supplemented with 8μg/ml de polybrene. MEFs were incubated 
with the viral supernatants for 8 hours. In the cases when secondary 
infections were needed, new fresh supernatants were added in the same way. 
48 hours after infection cells were selected with 2 μg/ml puromycin during at 
least 48 hours. shRNAs were validated in previous studies (Dickins et al., 
2007; Li et al., 2009) 
2.1.5. -gal staining  
At 17.5 day of gestation the female was sacrificed and embryos were 
extracted. A little piece of tail was cut for genotyping purposes and the rest of 
the embryo was fixed in 2% formaldehyde, 0,2% glutaraldehyde in PBS for 
45 minutes. After this, it was washed twice with PBS and incubated overnight 
in a staining solution at 37°C in a shaking incubator. 
The cells were fixed directly in the cell culture plate, washed and 
stained with the very same solution, according to the instructions of the 
Senescence -Galactosidase Staining Kit (Cell Signaling). Pictures were later 
taken with a bright field microscope connected to a digital camera.  
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2.1.6. Cell cycle and G2/M checkpoint measurements 
5x105- 106 cells were harvested as usual; they were fixed with cold PBS 
70% ethanol. After this, cells were permeabilized with 0,25%TritonX-100 in 
PBS during15 minute in ice. After centrifugation, cells were incubated with 
0,75ug of the primary antibody that detects Histone 3 phosphorylation in 
serine 10 (Upstate 06-570) -an epigenetic mark of mitosis entrance- 
dissolved in BSA 1% in PBS (blocking solution) for 3 hours at room 
temperature. Next, cells were washed with this solution and incubated for 30 
minutes at room temperature with a 1/200 dilution of the secondary 
antibody conjugated to Alexa 488. Finally, cells were washed and 
resuspended in blocking solution with 10ug/ml of propidium iodide and 
100ug/ml RNase. After an overnight incubation at 4°C or 30 minutes one at 
room temperature, cell cycle and phosphorylation were analyzed in a BD 
FACSCanto II cytometer using a laser of 488 nm and a 530/30-Blue detector 
to measure Alexa488 and a 585/42-Blue detector for propidium iodide. Data 
were analyzed with the program Flowjo. 
2.2. Molecular Biology  
2.2.1. Western blot 
The following primary antibodies were used:  Anti-Actin (Sigma 
A5441), anti H2AX (Millipore), anti-ATR (Serotec AHP386), anti-p16INK4a 
(M-156 Santa Cruz), anti-p19ARF (Santa Cruz 32748), anti-caspase3 ((R&D 
Systems); Histone 3 phosphorylation in serine 10 (Upstate 06-570) 
Cells were lysate by incubation a minimum of 15 minutes in ice with 
RIPA solution (Tris-HCl pH 7.4 50 mM, NP-40 1%, Na-deoxycolate 0.25%, 
NaCl 150 mM and EDTA 1 mM) supplemented with protease (Sigma-Aldrich) 
and phosphatase (Sigma-Aldrich). After this, lysates were centrifuged at 
16000 g to eliminate cell debris. Bradford method was used to determine 
protein concentration. Extracts were denaturalized by heat – 5minutes 
incubation at 99°C- and separated in gradient gels 4-12% SDS-PAGE (Tris-
Acetate Nupage Novex, Invitrogen). Proteins were later wet- transferred to 
nitrocellulose membranes (Hybond ECL Nitrocellulose, Amersham). Once the 
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transference has been done, membranes are incubated for 30 minutes at 
room temperature in blocking solution (5% skimmed milk (Central Lechera 
Asturiana) in TBS Tween20 0.1% -TBS-T). Membranes are later incubated 
overnight at 4°C with primary antibodies diluted in blocking solution. After 
washing the membranes 3 times with TBS-T, they are incubated during 1 
hour at room temperature with secondary antibodies that are already 
conjugated to a fluorophore. Proteins are visualized with Li-cor scanner that 
allows digital acquisition for quantitative analysis. 
2.2.2. High throughput microscopy (HTM) 
Cells were cultivated in 96 wells plates with a flat crystal bottom 
(Greiner Bio-One). After applying the corresponding treatments – when 
needed- to the cells,  they were fixed with 2% paraformaldehyde in PBS at 
room temperature during 5 minutes. After this, they were permeabilized 
with a solution containing 0,1% sodium citrate and 0,1% Triton X-100 during 
5 minutes. After washing three times with 0,25% BSA, 0,1%Tween20 in PBS, 
cells were incubated in blocking solution (2,5%BSA, 0,1%Tween20, 10% goat 
serum) for 30 minutes. Incubation with the corresponding primary antibody 
diluted in blocking solution took place overnight at 4°C and, after washing 3 
times the secondary antibody conjugated to a fluorophore was added. This 
secondary antibody was also washed and, finally, nuclei were stained with a 
DAPI containing solution. 
When Edu (5-ethynyl 2’-deoxyuridin) staining was required, cells were 
treated with Edu and after 30minutes to 1 hour, depending on the cellular 
replication rate, cells were fixed with 4% paraformaldehyde in PBS at room 
temperature during 5 minutes. After this, Click-iT Edu Cell proliferation 
Assay kit (Life Technologies) was used to stain the incorporated nucleoside. 
Images were acquired automatically with the robotic microscope BD 
Pathway 855 BioImager (Beckton Dickinson) at room temperature and using 
a dry objective with a magnification of 20x or 40x. The analysis of the 
acquired images and quantification of the fluorescence signal was performed 
with AttoVision software (Beckton Dickinson). This method allows 
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acquisition of images in an automatic way and their later analysis is 
described below.  
The robotic microscope takes pictures from different fields in each well, 
in the different fluorescence channels depending on a programmable 
mATRix. Once the pictures have been acquired, the analysis software allows 
the delimitation of regions of interest that are identified as individual objects 
according to certain visual parameters. In our case, each nucleus is 
recognized by the difference in the intensity of DNA staining with DAPI 
between the nuclei itself and the background. This way, we define a stencil of 
objects that allows us to filtrate the pictures captured in each channel, being 
able to analyze different parameters inside these objects. For instance, we 
can analyze the fluorescence intensity of different channels inside the 
nucleus. A list with all the objects (i.e. nuclei) and analyzed parameters (i.e. 
Fluorescence intensity) is generated and all these data can be represented 
directly in a graph, linking every object to a point in the graph. More complex 
analysis, like the identification of other objects inside the ones that have 
already been defined, can also be done.   
In our case, we use HTM to measure gH2AX or EdU intensity in DAPI 
stained nuclei. 
2.2.3. RNA extraction and analysis 
Cells were harvested as usual Absolutely RNA Nano or Microprep Kits 
were used to isolate RNA. Samples harvested at different time points were 
stored in lysis buffer at -80°C and the extraction protocol was performed at 
the same time in all samples.  
The extraction protocol consists of a column chromatography and 
includes a DNase treatment step. After the extraction, samples were stored at 
-80°C. 
p16INK4a and p19ARF RNA levels were measured by a quantitative 
reverse transcription polymerase chance reaction. To this aim, 0,4 µg of RNA 
were used in a mix reaction according to the instructions of SuperScript III 
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Platinum kit (Invitrogen) that contains Sybr Green. The curve was 
normalized to the corresponding GAPDH levels of each sample. The 
oligonucleotides used were:  
GAPDH Rev:   CATGATGGCCATGAGGTCCACCAC 
GAPDH Fwd:   GCCACCCAGAAGACTGTGGATGGC 
p16INK4a Rev:  TTGAGCAGAAGAGCTGCTACGT 
p16INK4a Fwd:  CGTACCCCGATTCAGTGAT 
p19ARF Rev:  TTGAGCAGAAGAGCTGCTACGT 
p19ARF Fwd:  GCCGCACCGAATCCT
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RESULTS 
1. Rescue of senescence on ATR-Seckel MEF 
1.1. T121 recues senescence on ATR-Seckel MEF 
Mouse Embryonic Fibroblasts (MEF) are a very useful tool to study the 
consequences of genetic alterations in a in vitro setting. However, one of the 
technical disadvantages of cultivating primary cells is that they eventually stop 
proliferating and enter senescence. This is particularly true in the case of ATR-
Seckel MEF, that stop proliferating at approximately 5 passages. Moreover, and in 
contrast to WT MEF, ATR-Seckel MEF do not spontaneously immortalize and we 
also failed to immortalize them by p53 deletion or by the addition of MYC or 
RAS/E1A oncogenes. Hence, to understand whether immortalization of cells with 
reduced ATR levels was at all possible became a key objective in our laboratory. 
MEF can be immortalized by serial passage, when a stochastic genetic event – 
either p53 or P19ARF loss (Collado et al., 2007; Kamijo et al., 1997)- occurs. ATR- 
Seckel MEF spontaneous immortalization occurs very rarely and only if ATR levels 
are regained (Murga et al., 2009). Another classical way to immortalize MEF is the 
addition of certain oncogenes. One of the most common oncoprotein used is the 
large T antigen; an oncoprotein contained in the SV40 polyomavirus. This 
oncoprotein is able to control very important signaling pathways in order to 
promote cellular proliferation, what will induce transformation of virus-infected 
cells. More precisely, the T-large antigen is able to bind and inactivate the two 
major tumor suppressor RB and p53 (Colby and Shenk, 1982; Jat and Sharp, 1986; 
Todaro et al., 1966). Given that loss of p53, not only does not rescue, but rather 
aggravates the phenotypes of ATR-Seckel MEF (Murga et al., 2009), we decided to 
explore the impact of the expression of a fragment of the large T antigen (T121, the 
first 121 aa), which inactivates the whole retinoblastoma family of proteins (RB, 
p107, p130), but does not affect p53 (Chen et al., 1992). In contrast with p53 
deletion, expression of T121 fully rescued the growth of ATR-Seckel MEF, this 
being the first case in which ATR-Seckel MEF could be immortalized (Figure 1). 
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Figure 1. T121 recues senescence on ATR-Seckel MEF  Growth curve of ATR+/+ and ATRs/s MEF 
that have been infected with a control retrovirus or a retrovirus expressing T121 oncoprotein. 
Error bars indicate standard deviation (n=3). 
1.1.1. T121 infected ATR-Seckel MEF maintain low ATR and high RS levels 
ATR- Seckel MEF immortalization by T121 expression could be due to 
different reasons, such us a regain in ATR protein levels, the disappearance of the 
RS characteristic of ATR-Seckel MEF or, more interestingly, the capacity of ATR 
hypomorphic cells to proliferate indefinitely while they still accumulate high levels 
of RS. We decided to investigate these options.  
First, growing cultures of T121 infected ATR-Seckel MEF show ATR levels 
equivalent to ATR-Seckel cells (Figure 2B). The fact that T121 expressing ATR-
Seckel MEF maintain low ATR levels, suggested that these MEF could be growing in 
the presence of RS. In mammalian cells, RS leads to phosphorylation of the histone 
H2A variant H2AX, which has been previously be proven to be a very rigorous RS 
marker when measured by high throughput microscopy (HTM) (Murga et al., 
2011; Toledo et al., 2011b). As shown below, growing cultures of T121 ATR-Seckel 
MEF are able to grow with substantial levels of RS (Figure 2A). Of note, T121 
infected ATR-Seckel MEF show slightly lower RS levels than ATR-Seckel MEF 
infected with a control retrovirus. We believe that this small difference might be 
due to the death of T121-infected cells accumulating high amounts of RS, since 
very high levels of basal cell death are observed in culture.  
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Consistent with high RS levels, T121-expressing ATR-Seckel MEF also 
present an accumulation of cells in G2, which is a typical outcome of RS and also 
found on ATR-Seckel MEF (Murga et al., 2009) (Figure 2C). In summary, T121 
infection allows the growth of ATR- Seckel MEF in the presence of high doses of RS. 
 
Figure 2. T121 ATRs/s MEF maintain low ATR levels, high RS dosis and G2 arrest (A) HTM 
mediated quantification of the nuclear levels of H2AX in ATR+/+ and ATRs/s infected with a control 
retrovirus or with a retrovirus containing T121. (B) Western Blot analysis of ATR levels in wt MEF 
as well as in ATR-Seckel MEF that had been infected with a control retrovirus or with a retrovirus 
expressing T121. (C) Graphical representation of the percentage (%) of cells in each phase of the 
cell cycle. Consistent with the activation of the RS Checkpoint, T121 ATRs/s MEF show a greater 
accumulation in G2 compared to their wildtype equivalent T121 ATR+/+ MEF. 
1.2. INK4a/ARF downregulation rescues senescence on ATR-Seckel MEF 
Given that RB inactivation by T121 rescued the growth of ATR-Seckel MEF 
we decided to explore the consequences of the inactivation of other genes related 
to the RB pathway. Earlier studies in MEF showed that loss of the INK4a/ARF 
locus, which encodes for a regulator of RB, leads to the bypass of proliferation 
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induced senescence (Kamijo et al., 1997; Serrano et al., 1997). Thus, we decided to 
explore the impact of losing INK4a/ARF on ATR mutant cells. First, ATR-Seckel 
MEF were infected with retroviruses expressing short hairpin RNAs (shRNAs) 
targeting both products of the INK4a/ARF locus. These shRNAs had previously 
been validated in different studies (Dickins et al., 2007; Li et al., 2009). In contrast 
to MEF that had been infected with a control retrovirus, INK4a/ARF depletion 
rescued the proliferation of ATR-Seckel MEF (Figure 3). Of note, INK4a or ARF 
depletion (or genetic elimination, see below) alone, did not immortalize ATR-
Seckel MEF. 
 
Figure 3.  INK4a/ARF downregulation rescues senescence on ATR-Seckel MEF Growth curve 
of ATR s/s MEF that have been infected with a control retrovirus, or a retrovirus expressing shRNAs 
against p16INK4a, p19ARF or the whole locus INK4a/ARF. Error bars indicate standard deviation 
(n=3). 
1.2.1. INK4a/ARF depleted ATR-Seckel MEF maintain low ATR and high RS 
levels 
We then tested whether INK4a/ARF depletion had an impact on ATR levels, 
and found that growing cultures of ATR-Seckel MEF depleted for INK4a/ARF 
presented the same reduction of ATR as the one seen in ATR-Seckel cells (Figure 
4B). Additionally, shINK4a/ARF infected ATR-Seckel MEF kept high levels of RS 
(Figure 4A) and maintained the characteristic G2 accumulation associated to RS 
(Figure 4C). Of note, the infection with the retrovirus expressing INK4a/ARF 
shRNA increases G2 accumulation per se, what might be due to the loosening of the 
G1-S checkpoint associated to INK4a/ARF downregulation. These results are 
similar to what we found when ATR-Seckel MEF where infected with T121. 
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Figure 4. shRNA INK4a/ARF infected ATR s/s MEF maintain low ATR levels, high RS doses and 
G2 arrest (A) HTM mediated quantification of the nuclear levels of H2AX in ATR +/+ and ATR s/s 
infected with a control retrovirus or with a retrovirus containing a shRNA against INK4a/ARF. (B) 
Western Blot analysis of ATR levels in wt MEF as well as in ATR- Seckel MEF that had been infected 
with a control retrovirus or with a retrovirus expressing shINK4a/ARF or T121. (C) Graphical 
representation of the percentage (%) of cells in each phase of the cell cycle. In this case, it seems 
like the infection with the shRNA against INK4a/ARF increases G2 accumulation by itself. 
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2. INK4a/ARF regulates replication stress induced senescence 
2.1. p16INK4a and p19ARF are expressed upon RS 
In the following experiments we tried to understand the relationship 
between RS, the expression of the products of the INK4a/ARF locus and the onset 
of senescence. p16INK4a and p19ARF expression was measured by high throughput 
microscopy (HTM). Given the low expression and size of the two proteins, that 
usually makes their biochemical detection difficult, and in order to facilitate a 
precise quantification of p16INK4a and p19ARF levels, we decided to optimize a HTM 
assay that would allow us to quantify the expression of both proteins in every cell. 
We validated the specificity of the assay by including INK4a/ARF deficient MEF as 
a negative control for both signals (Figure 5A).  
2.1.1. p16INK4a and p19ARF are expressed upon HU and ATRi induced RS 
First, wild type (WT) MEF were treated with two RS inducing agents: 
hydroxyurea (HU) –an inhibitor of the ribonucleotide reductase that leads to 
nucleotide deficiency and, therefore, RS– and an ATR inhibitor (ATRi) recently 
developed in our group (Toledo et al., 2011b). As shown bellow, a persistent 
exposure to low doses of HU or ATRi led to the accumulation of cells with high 
levels of p16INK4a and p19ARF (Figure 5A), showing that a chronic exposure to 
replication stress boosts de expression of the whole INK4a/ARF locus. 
Moreover, and consistent with this, protein and mRNA levels of p16INK4a and 
p19ARF were also induced by replication stress inducing agents, as shown in the 
quantitative retrotranscriptase polymerase change reaction (QRT-PCR) data 
(Figure 5C) and Western blot depicted below (Figure 5B). 
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Figure 5. p16INK4a and p19ARF are expressed upon HU and ATRi induced RS (A) Quantification 
via HTM of H2AX, p16INK4a and p19ARF nuclear levels in wt MEF exposed to HU (0,5mM) and ATRi 
(1M) for 5 days. INK4a/ARF -/- MEF were included as a negative control. (B) Western Blot analysis 
of p16INK4a and p19ARF in WT MEF that had been exposed to ATRi for 5 days (50, 100 and 500nM). 
MEF infected with a retrovirus expressing RASV12 and E1A oncogenes were used as a positive 
control of INK4a/ARF activation. INK4ka/ARF-/- MEF were included as a negative control. (C) qRT- 
PCR analysis of the mRNA levels of p16INK4a  and p19ARF in wt MEF treated with ATRi 464 5nM 
during 2, 8 and 24 hours and with ATRi464 1nM during 5 days. INK4a/ARF-/- MEF were included as 
a negative control. mRNA levels were normalized to the expression of GAPDH in each case. Error 
bars indicate standard deviation (n=3).  
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2.1.2. p16INK4a and p19ARF are expressed upon endogenous RS 
We next measured p16INK4a and p19ARF levels in ATR-Seckel MEF which, as 
mentioned before, show high constitutive levels of RS. Consistent with the data 
obtained with HU or ATRi, the levels of both INK4a/ARF gene products were 
increased in these cells (Figure 6A). 
Given that we had used a HTM platform to measure p16INK4a and H2AX 
protein levels, we were able very accurately measure p16INK4a and H2AX in each 
individual cell. Therefore, we decided to plot the intensity of both markers to seek 
for any kind of correlation between p16INK4a expression and H2AX levels. 
Importantly, we found that p16INK4a and H2AX fluorescence intensity correlated 
on a cell-by-cell basis on ATR-Seckel mutant cells, further supporting that RS 
induces the expression of the INK4a/ARF locus (Figure 6B).  
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Figure 6. INK4a/ARF activation in response to endogenous RS (A) HTM mediated 
quantification of the nuclear levels of H2AX, p16INK4a and p19ARF in ATR+/+ and ATR s/s MEF. 
INK4a/ARF -/- MEF were included as a negative control. (B) 2D-plot showing the direct correlation 
between nuclear H2AX and p16INK4a levels found in ATR+/+ and ATR s/s MEF. In both cases (A and 
B), at least 2000  nuclei were quantified per condition *** p<0,001. 
2.2. INK4a/ARF deletion rescues RS- induced senescence  
ATR inhibitors are being explored in cancer therapy, particularly for tumors 
with high rates of RS (Toledo et al., 2011a).  Considering that loss of INK4a/ARF is 
a common event in human cancer, our previous results raised the question of 
whether those tumors might not be sensitive to ATR inhibition. In order to explore 
this possibility in depth, we developed the next set of experiments. 
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2.2.1. INK4a/ARF-/- MEF are resistant to RS- induced senescence 
Given that INK4a/ARF depletion was able to bypass RS-induced senescence 
in ATR-Seckel MEF, we decide to investigate whether INK4a/ARF depleted cells 
are overall more resistant to RS. To this end, we cultivated INK4a/ARF-/- and WT 
MEFs with RS-inducing agents. Precisely, the two cell types were exposed to low 
but chronic doses of HU and ATRi. In agreement with what has been explained 
hitherto, INK4a/ARF deficient MEF were able to maintain growth in the presence 
of the same ATRi or HU doses that induce senescence on WT MEF (Figure 7A). This 
piece of evidence proves that INK4a/ARF ablation is able to bypass senescence, not 
only when it is induced by proliferation or oncogenes, but also when it is activated 
by RS. Senescence-associated -galactosidase activity was used to confirm 
senescence in each independent culture (Dimri et al., 1995) (Figure 7B). 
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Figure 7. INK4a/ARF -/- MEF are resistant to RS- induced senescence (A) Proliferation curves of 
INK4a/ARF-/- and INK4a/ARF+/+ MEF chronically exposed to HU or ATRi at the doses indicated 
above. Error bars indicate standard deviation (n=3) (B) Images of the senescence-associated beta-
galactosidase activity in In4a/ARF+/+ and INK4a/ARF-/- cultures exposed to HU (0,1mM) or ATRi 
(2M) for 15 days. Images of untreated cells are included as controls. 
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2.2.2. ATR s/s INK4a/ARF-/- MEF bypass RS- induced senescence 
To explore the impact of INK4a/ARF loss in a scenario in which ATR activity 
is challenged, we generated INK4a/ARF-/- MEF in an ATR-Seckel background. 
Similar to our previous findings with shRNAs, INK4a/ARF ablation fully rescued 
the growth of ATR-Seckel MEF (Figure 8A). As before, INK4a/ARF deletion was 
able to rescue cell proliferation without restoring ATR protein levels (Figure 8B) or 
RS (Figure 8C-E).  
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Figure 8. ATR- Seckel INK4a/ARF -/- MEF bypass RS- induced senescence (A) Proliferation 
curves of ATR+/+ INK4a/ARF+/+, ATR+/+ INK4a/ARF-/-, ATRs/s INK4a/ARF+/+ and ATRs/s INK4a/ARF-/- 
MEF. Error bars indicate standard deviation (n=3) (B) Western Blot analysis of ATR levels in ATR+/+ 
INK4a/ARF+/+, ATR+/+ INK4a/ARF-/-, ATRs/s INK4a/ARF+/+ and ATRs/s INK4a/ARF-/- MEF. (C) 
Representative examples of the H2AX staining used for HTM in the next image. DAPI (blue) was 
used to stain DNA. Scale bar (white) indicates 10m (D). Quantification via HTM of H2AX levels 
per nucleus on ATR+/+ INK4a/ARF+/+, ATR+/+ INK4a/ARF-/-, ATRs/s INK4a/ARF+/+ and ATRs/s 
INK4a/ARF-/- MEF. (E). Graphical representation of the percentage (%) of cells in each phase of the 
cell cycle.  
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Once again, and consistent with our shRNA experiments, this rescue was only 
true for the deletion of the whole locus, but not for the ablation of p16INK4a or 
p19ARF independently (Figure 9 A, B). In either case, deletion of p16INK4a or p19ARF 
did not affect ATR protein levels (Figure 9 C, D), and double-mutant cells kept high 
levels of RS (Figure 9 E, F). 
 
Figure 9. ATR- Seckel p16 INK4a-/- or ATR-Seckel p19 ARF-/- MEF are not resistant to endogenous 
RS- induced senescence In this figure we characterise ATR+/+ P19ARF+/+ , ATR+/+ p19ARF -/-, ATRs/s 
p19ARF+/+ and ATR s/s p19ARF-/- MEF  and ATR +/+ p16 INK4a+/+, ATR+/+ p16 INK4a -/- , ATR s/s p16 INK4a +/+ 
and ATR s/s p16 INK4a -/- MEF. (A and B) Proliferation curves. Error bars indicate standard deviation 
(n=3). (C and D) Western Blot analysis of ATR levels. (E and F) Quantification via HTM of H2AX 
levels in every nucleus. 
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3. INK4a/ARF has a limited role on ATR-Seckel in vivo phenotypes  
3.1. INK4a/ARF depletion does not rescue the ageing phenotype of ATR-
Seckel mice 
To learn about the impact of INK4a/ARF loss on limited ATR activity in vivo, 
ATR-Seckel; INK4a/ARF-/- mice were generated. INK4a/ARF-/- mice are viable and 
fertile, however, they have an increased susceptibility to the development of 
cancer (Serrano et al., 1996). ATR-Seckel mice die within 4-6 months due to a 
pleotropic progeroid disease. Surprisingly, despite the rescue of MEF senescence, 
INK4a/ARF deletion did not have any effect on the lifespan of ATR- Seckel mice 
(Figure 10B). Moreover, the loss of INK4a/ARF did not significantly rescue the sub-
Mendelian ratios at which ATR-Seckel mice are born (Figure 10A).  
 
Figure 10.     INK4a / ARF depletion  does not rescue early  death  onset  or  low birth  ratio  of  
ATR-Seckel mice   (A)   Birth   ratio of ATR-Seckel  mice born from several   matings   between two  
ATR s/+ ;  INK4a/ARF-/+ mice  .   5 4 0   total   births   were analyzed. Birth ratios (%)  are relative   to  
ATR-Seckel mice  only.  (B) Kaplan - Mejer analysis of    the   lifespan   of  ATR s/s INK4a / ARF +/+   or   
ATR s/s Innk4a / ARF +/- ,    ATR s/s INK4a / ARF -/-  and  ATR+/+ or ATRs/+ INK4a/ARF-/- mice.  
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We also analyzed in detail whether INK4/ARF loss affected any of the 
phenotypes that are found on ATR-Seckel mice. ATR-Seckel mice present a 
dramatic retardation of intrauterine development, which results in a low size and 
weight at birth. This growth retardation is already evident at the embryonic state, 
when mice are born and it continues during adulthood, when the differences 
among littermates increase. No noticeable differences were detectable between the 
overall appearance of ATRs/s and ATRs/s ; INK4a/ARF -/- mice (Figure 11). 
Figure 11. INK4a/ARF depletion does not rescue ATR-Seckel mice phenotypes Representative 
pictures of ATRs/s INK4a/ARF+/+ , ATRs/s INK4a/ARF-/-  and ATR+/+ INK4a/ARF +/+ mice. 
 
Besides their overall phenotype, ATR-Seckel mice present a numbef or ageing 
phenotypes at an early age such as hair graying, cachexia, kyphosis, and 
accumulation of adipose tissue in their bone marrow or low bone mineral density. 
Other ageing symptoms that we have detected in these mice include increased 
polyploidy in liver, reduced hair follicle density and thinner epidermis, as well as 
severe pancitopenia. Once again, we were unable to find any obvious differences 
between ATRs/s and ATRs/s; INK4a/ARF-/- mice on any of these phenotypes (Figure 
12). 
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Figura 12. INK4a/ARF depletion does not rescue ATR-Seckel mice phenotypes (A) 
Hematoxilin & Eosin stained sections of paraffin embedded blocks of skin and bone marrow of 
ATR+/+ INK4a/ARF-/-, ATRs/s INK4a/ARF+/+  and ATRs/s INK4a/ARF-/- and mice. All ATR- Seckel mice 
show very thin skin (black line) and fat deposits in their bone marrow (signaled with arrows) (B) 
Bone mineral density was lower in ATR-Seckel mice, without guarding any relationship with INK4a 
status. (C) Body weight of ATR-Seckel mice was lower with independence of INK4a/ARF status. (D) 
Red Blood Cell count was diminis in ATRs/s independently from INK4a/ARF status. 
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Finally, we tested the effects of the individual deletion of p16INK4a or p19ARF 
on an ATR-Seckel background. Surprisingly, deletion of either gene not only failed 
to rescue the ATR mutant phenotype but rather led to an aggravation of the 
disease . First, the birth ratios of ATR-Seckel animals deleted for either p16INK4a or 
p19ARF are extremely low (Figure 13 A and B). Given that ATR-Seckel mice lacking 
p16INK4a or p19ARF are born with such a low frequency, we mated ATRs/+ mice 
nullizigous for either p16INK4a or p19ARF in order to obtain enough ATR-Seckel mice 
lacking each of the components of the INK4a/ARF locus. However, this did not help 
significantly in the case of p19ARF, where we only obtained two ATRs/s p19ARF-/- 
mice, which even if they were markedly progeroid, was an insufficient number to 
analyze their ageing curve (Figure 13). As for the case of p16INK4a, ATRs/s p16INK4a-/- 
mice show a very marked progeroid phenotype and die significantly earlier than 
ATRs/s p16INK4a+/+ littermates (Figure 13C).  
In summary, and even though the senescence of ATR-Seckel MEF is rescued 
by the loss of INK4a/ARF, the phenotype is of ATR-Seckel mice is not altered by the 
depletion of the whole INK4a/ARF locus. On the contrary, the severity of the 
symptoms is exacerbated by the individual elimination of either p16INK4a or p19ARF. 
One possibility to explain this paradox could result by the compensatory 
expression at the locys. When p16INK4a is not present, more p19ARF is expressed, 
and vice versa, leading to an increased cell cycle arrest in each case which could 
worsen the phenotype (Baker et al., 2008). 
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Figura 13. Individual deletion of p16INK4a or p19ARF worsens ATR-Seckel mice phenotype (A) 
Birth ratio of ATR-Seckel mice born from several matings between two ATRs/+; p16INK4a+/- mice. 191 
births were analyzed. Birth ratios (%) are relative to ATR-Seckel mice only.  (B) Birth ratio of the 
different genotypes born from several matings between two ATRs/+; p19ARF+/- mice. 191 births were 
analyzed. Birth ratios (%) are relative to ATR-Seckel mice only. (C) Kaplan- Mejer analysis of the 
lifespan of ATRs/s p16INK4a+/+ or ATRs/s p16INK4a+/-, ATRs/s p16INK4a-/- and ATR+/+ or ATRs/+ p16INK4a-/- 
mice. Kaplan- Mejer analysis of ATRs/s p19ARF-/- mice was not possible given that we only two mice 
with this genotype were born. 
3.1.1. Cancer and ATR Seckel mice 
Low levels of ATR have been shown to be synthetic lethal with mutations that 
promote cancer, such as p53 ablation (Murga et al., 2009) or MYC overexpression 
(Murga et al., 2011). Given that T121 expression or INK4a/ARF deletion were able 
to immortalize ATR-Seckel MEF the question was whether any of these conditions 
could also promote cancer in an ATR-Seckel background. Whereas ATR-
Seckel;INK4A/ARF double mutant mice die prematurely due to the progeroid 
disease, we should notice that after more than 5 years of research with the ATR-
Seckel strain, the only tumor ever found on these animals was a fibrosarcoma 
found at 12 weeks of age on an INK4/ARF deleted ATR-Seckel mouse. The reason 
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of not finding more tumors could be related to senescence playing a less important 
role than cell death in vivo on the ATR-Seckel phenotype. Given that most of the cell 
death in ATR-Seckel mice occurs during embryonic development, we propose that 
a better model to study the interaction between INK4a/ARF and ATR in cancer 
could be associated to the targeting of ATR on adult INK4A/ARF mice (Gilad et al 
2012).  
3.2. ATR-Seckel phenotype is more related to cell death than to 
senescence. 
As mentioned, one possible way to explain the reduced impact of INK4a/ARF 
loss on the ATR-Seckel phenotypes, despite its impact on MEF senescence is that, 
in vivo, cell death rather than senescence is the main determinant of the progeroid 
disease. Several facts support this hypothesis. On one hand, we were unable to find 
any evidences of senescence in ATR-Seckel embryos, in contrast to what is 
observed on a mouse BRCA1 mutant model (delta-11) which was previously 
reported to show senescence during development (Cao et al., 2003) (Figure 14A). 
On the other hand, and as reported before (López-Contreras et al., 2012; Murga et 
al., 2009), ATR-Seckel embryos showed substantial amounts of apoptosis – 
measured by immunochemistry against activated caspase 3-, which correlate with 
the severity of the progeroid phenotype in adult mice.  
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Figure 14. Evidences of apoptosis- but not senescence- on ATR-Seckel embryos (A) Images of 
ATR+/+ and ATRs/s littermate embryos (right panel) in which whole mount SA-b-galactosidase 
activity was measured (blue) as a senescence marker. Littermate embryos of a BRCA1 mutant 
mouse model (delta-11), which have been previously reported to show senescence during 
embryonic development (Brown and Baltimore, 2000) were included as a positive control (left 
panel). (B) As it had already been reported (Murga et al., 2009), ATR- Seckel embryos show 
considerable levels of apoptosis. This was measured by immunohistochemistry against activated 
caspase 3 (brown, indicated with black arrows). The staining was also present on ATRs/s 
INK4a/ARF -/- littermate embryos. Scale bar indicates 50m. 
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3.3. INK4a/ARF depletion rescues senescence but not cell death 
As stated in point 2.2.2., the loss of INK4a/ARF rescues senescence in ATR-
Seckel MEF. To explore whether INK4a/ARF deletion is also able to rescue RS-
induced cell death we exposed INK4a/ARF-/- cells that are more prone to cell death 
than to senescence – such as splenocytes- to ATR inhibitors. WT and INK4/ARF 
null splenocytes were exposed to increasing doses of ATRi. After 24 hours of 
treatment, we calculated the percentage of dead cells by measuring the frequency 
of cells with a subG1 DNA content based on the intensity of propidium iodide 
through flow cytometry. In contrast to its impact on senescence, INK4a/ARF failed 
to modify the cytotoxic effects of ATRi (Figure 15A). Likewise, an in vivo treatment 
of mice with 5mg/kg of the CHK1 inhibitor UCN-01 leads to RS and apoptosis in the 
thymus – measured by H2AX and activated caspase 3 immunochemistry 
respectively - independently of INK4a/ARF status (Figure 15B). All the above 
suggest that cell death rather than senescence is the main outcome to a limited 
ATR function in vivo. 
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Figure15. INK4a/ARF 
ablation does not modify 
the cytotoxic response to 
ATRi (A) INK4a/ARF+/+ and 
INK4a/ARF-/- splenocytes 
were stimulated for 48 hours 
with lipopolysaccharide 
(10g/ml) and exposed to 
ATRi for 24h at the indicated 
doses. The percentage of 
dead cells was calculated by 
measuring the frequency of 
cells with a subG1 DNA 
content based on the 
intensity of propidium 
iodide observe in a 
citometer. Error bars 
indicate standard deviation 
(n=3). (B) INK4a/ARF+/+ and 
INK4a/ARF-/- mice were 
injected intraperitoneally 
with the CHK1i UCN01 
(5mg/kg). The images show 
the immunochemistry 
analysis of H2AX and 
caspase 3 in each case. 
4. Contribution of INK4a/ARF to the RS- response in a cancer context 
The small impact of INK4a/ARF ablation on ATR-Seckel mice, contrasts with 
its role in the regulation of RS-induced senescence in MEF. To explain this disparity 
we propose that INK4a/ARF dependent senescence would be the result of a 
persistent exposure to limited amounts of RS, such as in the case of MEF exposed 
to low doses of HU or ATRi for long times. On the contrary, high amounts of RS 
would inevitably lead to cytotoxicity since cells would not be able to divide in the 
presence of regions that have not been replicated. This would be of particular 
importance in the case of ATR inhibitors, where the drugs would not only alter 
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DNA replication, but also abrogate the checkpoint activity that limits the entry into 
mitosis with unreplicated DNA. In agreement with the proposed model, and even if 
INK4a/ARF-/- MEF grow more when chronically exposed to low doses of ATRi, they 
show the same sensitivity as WT MEF to acute, high ATRi doses (Figure16). This 
piece of data suggested that the cytotocity of ATR inhibitors in cancer would not be 
modified by mutations in the INK4a/ARF locus.  
 
Figure16. INK4a/ARF-/- cells are sensitive to acute ATRi treatments INK4a/ARF+/+ and 
INK4a/ARF-/- MEF were exposed to ATRi at the indicated doses for 24h, and the number of cells 
alive was counted. Numbers indicate the percentage of cells alive after the treatment (relative to 
untreated ones). Error bars indicate standard deviation (n=3) 
4.1. INK4a/ARF or p53 status does not limit the toxicity of ATR or CHK1 
inhibitors in cancer cell lines.  
To further support the model presented in the previous point, we tested the 
toxicity of ATRi and UCN-01 in pancreatic ductal adenocarcinoma (PDAC) cell lines 
established from a mouse model of K-RASV12- induced tumorigenesis (Guerra et 
al., 2003) which were wt, p53-/- or INK4a/ARF-/-. Importantly, ATRi was cytotoxic 
for all of the lines regardless of their p53 or INK4a/ARF status (Figure 17). 
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Figure 17. INK4a/ARF or p53 status does not limit the toxicity of ATR or CHK1 inhibitors in 
cancer cell lines To test our hypothesis in a cancer model system that is as genetically 
homogeneous as possible, we used murine pancreatic adenocarcinoma cell lines from a mouse 
model of K-RASV12- induced tumorogenesis (Guerra et al., 2003), which were wt, p53-/- or 
INK4a/ARF-/-. Cells from these cancer cell lines were exposed to ATRi (10M) or CHK1i (UCN-01, 
300nM) for 24h, and the number of alive cells was counted. Numbers indicate the percentage of 
alive cells after the treatment (relative to untreated ones). The indexed numbers indicate several 
independent INK4a/ARF deficient lines. Error bars represent standard deviation (n=3).  
4.2. Human cancer cell lines with high number of CNVs tend to present 
low p16INK4a  levels  
Notwithstanding of its limited influence on the ATR-Seckel phenotype, the 
RS-induced senescence pathway discovered during this thesis might still play an 
important role in cancer, where cells could be exposed to low but persistent doses 
of RS that could promote senescence rather than cell death. For instance, this 
might be happening in response to oncogenes. In fact, oncogene-induced 
senescence was already associated with increased p16INK4a levels since its 
discovery (Serrano et al., 1997). Moreover, more recent works suggested that 
oncogene-induced senescence could be secondary to the accumulation of 
oncogene-induced RS (Bartkova et al., 2006; Di Micco et al., 2006), which would in 
turn be the origin of the activated DNA Damage Response that is observed in 
cancer (Bartkova et al., 2005; Gorgoulis et al., 2005; Halazonetis et al., 2008). 
Taking this into account, the results exposed here could indicate that one of the 
roles of INK4a/ARF in the context of cancer could be  to limit the expansion of cells 
suffering from oncogene-induced RS. In agreement with this idea, INK4a/ARF 
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ablation facilitates MEF transformation with oncogenes (Li et al., 2009; Serrano et 
al., 1997). 
To investigate this hypothesis on a large dataset of human tumors, we took 
advantage of the Cancer Cell Line Encyclopedia (CCLE) project (Garnett et al., 
2012) that contains genomewide gene expression and copy number variant (CNV) 
data for 947 human cancer cell lines of different origin. Given that CNVs are the 
result of a persistent exposure to RS (Arlt et al., 2012), we assessed the connection 
between the expression of p16INK4a and the total number of CNVs of every cell line 
in the CCLE. To this aim, the expression levels of p16INK4a and the total number of 
CNV events of the 947 human cancer cell lines were plotted against each other. 
Interestingly, we found an inverse correlation between the two parameters, which 
was particularly evident on the cell lines with the highest number of CNV 
(P:0,0023). In other words: human cancer cells with high number of CNVs tend to 
present low levels of p16INK4a (Figure 18). Unfortunately, we were unable to run 
the same type of analysis for p19ARF, since no unique probes for this product were 
available in the CCLE dataset. Nonetheless, p16INK4a is considered the main 
contributor of the INK4a/ARF locus to tumor suppression in humans (Kim and 
Sharpless, 2006). Consistent with this key role of p16INK4a, it is worth mentioning 
that its tumor suppressor activity is linked to the RB pathway. In this context, the 
only other condition -besides INK4a/ARF deletion- that rescues the growth of 
ATR-Seckel MEF is the inhibition of RB through the expression of T121 (point 1.1.). 
Consistent with ATR expression being constitutive, we failed to found a 
similar correlation between ATR levels and the number of CNVs, what strengths 
the validity of the inverse correlation found between p16INK4a levels and the 
number of CNVs. Additionally, and on the contrary to p16INK4a, there was an 
opposite trend between p53 expression and CNVs (cells with high CNV levels tend 
to present a high p53 expression). However, tumors with high p53 levels are 
frequently associated to mutant p53 versions (Muller and Vousden, 2013). In 
summary, there was a specific trend to present low levels of p16INK4a expression 
among tumors that accumulate high levels of CNV, which are known to be the 
outcome to RS. 
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Figure 18. Correlation between p6INK4a mRNA levels and CNV events in human cancer cell 
lines The expression levels of p16INK4a and the total number of CNV events for 947 human cancer 
cell lines were obtained from the publicly accessible Cancer Cell Line Encyclopedia (CCLE) 
repository (Garnett et al., 2012) and plotted against each other. The boomerang shape of the 
distribution suggests that there is an inverse correlation between p16INK4a and the number of CNVs. 
To judge the statistical significance of the observation the levels of p16INK4a were compared 
between the top outliers (3% of the cell lines showing the highest number of CNV) and the rest of 
the cell lines, which proved that cells with the highest number of CNV present lower p16INK4a levels. 
(t-test ,P= 0,0023) In agreement with ATR expression being constitutive, we failed to observe a 
similar boomerang shame distribution with ATR. Interestingly, and in contrast to p16INK4a, cells 
with high CNV levels tend to present high levels of p53 expression.  
5. Exploring the relationship between ATR and RB  
Given that T121 expression allowed the immortalization of ATR-Seckel MEF 
and that T121 oncoprotein inhibits RB we decide to explore both the outcomes of 
T121 expression and RB deletion in an ATR-Seckel background. To this aim, we 
tried to generate a conditional T121 transgenic mouse model, which would be 
used for crossing it into ATR-Seckel. Additionally, RB conditional knockout mice 
were obtained for a similar purpose. 
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First of all, we decided to generate a new T121 transgenic mouse model that 
would allow us to control T121 antigen expression with a tetracycline inducible 
system. Our hypothesis was that these mice could develop widespread tumors 
upon T121 induction, which we could then study on the context of reduced ATR 
levels. To this end, we used a site-specific recombination strategy that enables the 
integration of the transgene at a specific locus that is widely expressed 
(collagenase), and under the control of the Tet-O promoter (Beard et al., 2006; 
Urlinger et al., 2000) (Figure 18). 
 
Figure 19. Generation of a T121 conditional mouse model (A) Strategy followed to introduce 
T121 in the Col1a1 locus, under the control of a tetracycline induced Operon, in cells that already 
contain a tretraCyclin transactivator domain (rtTA). (B) Southern blot of the hygromicin resistant 
clones, most of them had incorporated the Flp allele that contains T121. 
 
Unfortunately, even if we were able to find many embryonic stem (ES) cells 
with a proper integration of the system, aggregation of these ES cells that had 
incorporated the transgene invariably gave rise to unviable chimeras that would 
either die perinatally or be hermaphrodite and, therefore sterile. We tried the 
strategy twice with two different clones of ES cells from independent 
electroporations, but we chimeras always found the same problem. We think that 
this might be due the Tet system being slightly leaky, which might be fatal in the 
context of proteins such as T121 during embryonic development. In fact, T121 
expression has previously been shown to cause severe brain defects in mice (Sáenz 
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Robles and Pipas, 2009; Xiao et al., 2002). Moreover, when we tested the specificity 
of our system, we observed certain T121 expression in cells that carried the T121 
transgene in control conditions. This expression was increased by 30 fold in the 
presence of doxicycline (Figure 20A). Using these ES cells, we tested the impact of 
T121 expression on RS. To this end, we treated WT and T121TG ES that expressed 
T121 under the Tet-O promoter with tetracycline and subsequently exposed them 
to the CHK1 inhibitor UCN01. The expression of T121 increased proliferation and 
therefore RS levels in both, UCN01 treated and untreated, cells (Figure 20B). Thus, 
T121 expression leads to RS in murine ES. 
 
Figure 20. T121 expression increases RS (A) qRT-PCR analysis of the mRNA levels of T121 in WT 
and T121 inducible SC in control media and treated with doxicyclin. Only doxicyclin treated 
transgenic ESC show T121 expression. mRNA levels were normalized to the expression of GAPDH 
in each case. (B)Quantification via HTM of H2AX levels in every nucleus found on Col1aT121 +/+ 
and Col1aT121 +/T ESC treated with doxicyclin compared to control ones in a neutral situation or 
boosting replication stress levels with a 8 h treatment of CHK1i (UCN-01 300nM). 
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Following a different approach, we decided to generate a conditional knock 
out model for RB in an ATR-Seckel background. To this aim, we mated ATR-Seckel 
mice with mice carrying a pRBlox/lox allele and a tamoxifen-inducible UbCreERT-2 
transgenic allele. Using these mice, RB can be depleted in adult mice upon 
tamoxifen treatment therefore circumbenting the problem of embryonic lethality. 
We tested different administration strategies and patterns. However, this approach 
faced serious technical challenges that precluded the development of the 
experiment. Experimental mice ATRs/s; pRBlox/lox; UbCreERT-2T/+ were born at a 
very low ratio and, when exposed to the different tamoxifen treatments, very often 
died due to the treatment (i.e. intratracheal gauge). In addition to this, we were 
able to see very limited phenotypes linked to RB deletion in adult mice. RB lox/lox; 
UbCreERT-2 T/+ mice fed with tamoxifen diet during 4 weeks showed very mild 
phenotypes, the most striking being an increase in the mitotic index of the liver. 
Taking all this into consideration, we decided to discontinue the experiment. 
Regardless of being unable to do the experiment in vivo, we decided to exploit 
this pipeline to respond to a very basic question on RS-research; namely whereas 
cellular life is at all possible in the absence of ATR. ATR knockout mice are early 
embryonic lethal, and full deletion of ATR also leads to cell death in adult mice 
(Brown and Baltimore, 2000; Ruzankina et al., 2007) . However, based on our 
previous results, we decided to explore whether the expression of T121 was able 
to rescue the lethality of ATR null cells. To this end, we employed ATR conditional 
KO MEF (ATRlox/lox). ATRlox/lox MEF were first immortalized with T121. 
Subsequently, immortalized ATRlox/lox MEF were infected with a Cre recombinase 
expressing retrovirus carrying the puromycin resistance gene, to delete ATR. In 
this context, all puromycin resistant cells –the ones in which ATR had been 
eliminated- died within a few days (Figure 21). Thus, even if T121 is able to fully 
rescue senescence on ATR hypomorphic cells, it cannot rescue the viability of ATR 
nullyzygous cells. 
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Figure 21. ATR is essential for life (A)  WB  analysis  of  ATR levels  in ATRlox/lox  T121  expressing 
cells    infected  with  a  control  retrovirus or  with  a  retrovirus  expressing  Cre  recombinase. (B) 
Representative  examples  of  the  ATRlox/lox  and  ATRlox/lox T121 cells after the infection with  a  Cre 
expressing retrovirus.
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DISCUSSION 
RS is a type of DNA damage reflective of the accumulation ssDNA during 
replication, which triggers a cellular response coordinated by the essential protein 
ATR. As proof of the physiological impact of RS, ATR-hypomorph mice (ATR-
Seckel) present a progeroid disease to which they succumb early in life. Likewise, 
ATR-Seckel MEFs are unable to sustain proliferation due to the activation of RS 
induced senescence. Moreover, previous works from our group revealed that the 
severity of the ATR-Seckel mutation is aggravated through the loss of tumor 
suppressors like p53, or the gain of oncogenes like MYC, both of which further 
induce RS (Murga et al., 2009; Murga et al., 2011). Based on this synthetic lethal 
interaction with precancerous mutations, the use ATR or CHK1 inhibitors in cancer 
therapy might be particularly efficient in the context of mutations that drive RS. 
However, we have recently found that T121 expression or INK4a/ARF deletion can 
rescue growth on ATR-Seckel MEF, which raised the concern that the potential 
efficacy of ATR or CHK1 inhibitors for cancer therapy might be limited in tumors 
with deficiencies in these pathways. In this context, the aim of this PhD was to 
explore the genetic interactions between ATR and INK4a/ARF or RB in vitro and in 
vivo, and to investigate whether these mutations might limit the cytotoxicity of 
ATR and CHK1 inhibitors. 
1. The INK4a/ARF locus and genome maintenance 
As it was explained in greater detail in the introduction, p16INK4a was initially 
described as a CDK-interacting protein (Xiong et al., 1993), able to inhibit CDK4 
and CDK6 (Serrano et al., 1993). The locus also encoded another transcript called 
p19ARF that uses a different first exon and that shares the last 2 exons with 
p16INK4a, but in a different reading frame (Quelle et al., 1995b). Of note, p19ARF is 
not a CDK inhibitor but rather an activator of p53. All this taken into consideration, 
the INK4a/ARF locus is a key player in cancer: it activates the two core tumor 
suppressor pathways: p16INK4a/RB and p19ARF/p53. In human cells, however, 
p16INK4a seems to be the main contributor to tumor suppression. In fact, cancer-
associated mutations imply either the whole locus, or p16INK4a alone (Quelle et al., 
1995b).  
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Early studies unlinked INK4a/ARF from the response to DNA damage 
(Efeyan et al., 2006; Kamijo et al., 1999; Stott et al., 1998). In contrast, oncogenic 
stress was proven to activate p53 through the INK4a/ARF locus, suggesting that 
this was the only context where p53 activation would depend on p19ARF (Serrano 
et al., 1997). Accordingly, p19ARF deficiency does not alter the apoptosis induced by 
the activation of p53 in response to ionizing radiation in vivo. However, p19ARF is 
essential for p53 activation in response to oncogenic stress (Efeyan et al., 2006). In 
spite of all this, a number of reports also suggested a possible involvement of the 
locus in the response to DNA damage, (Al-Mohanna et al., 2007; Al-Mohanna et al., 
2004; Lau et al., 2007; Sarkar-Agrawal et al., 2004). One option to reconcile these 
observations is to consider that oncogenic stress could relate to chronic and low 
amounts of RS, which would constitute a source of persistent DNA Damage 
(Bartkova et al., 2005; Di Micco et al., 2006; Gorgoulis et al., 2005). Thus, it is 
possible that while INK4a/ARF does not play an active role in the acute response 
to DNA breaks, it might otherwise be important in the context of a chronic 
exposure to other sources of DNA damage such as replication stress. 
Consistent with the previous proposal, we show that low, but persistent 
amounts of RS can induce the expression of p16INK4 and p19ARF as well as 
INK4a/ARF-dependent senescence.  From the two products of the locus, a number 
of our observations point to p16INK4a as the main contributor to this phenomenon. 
First, while INK4a/ARF deletion rescues the senescence of ATR-Seckel MEF, p53 
ablation aggravates the phenotype of ATR-Seckel MEF and mice (Murga et al., 
2009). Second, a fragment of the large T antigen (aa. 1-121), which inactivates RB 
but not p53, also rescues senescence on ATR-Seckel MEF. Third, our qRT-PCR data 
show a greater increase in p16INK4a than in p19ARF expression upon treatment with 
reagents that induce RS. In agreement with this, it was earlier reported in our 
laboratory that RB is activated by a continuous exposure to doxorubicin, a drug 
that damages DNA during replication. Moreover, this activation was required to 
maintain a prolonged cell cycle arrest on the damaged cells (Cuadrado et al., 2009). 
Finally, our meta-analysis of the Cancer Cell Line Encyclopedia data shows that 
p16INK4a levels are exceptionally low on cancer cells with a high number of Copy 
Number Variations. Interestingly, we failed to observe a similar correlation 
between CNVs and the levels of ATR, which is the main kinase orchestrating the 
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response to RS but is expressed constitutively. In contrast to p16INK4a, cells with 
high CNV levels tend to present high levels of p53 expression. However, most 
tumors presenting high levels of p53 are associated with inactive mutant forms of 
the protein (Muller and Vousden, 2013). Thus, these pieces of data suggest that the 
relationship between p16INK4a low levels and a high number of CNV is not casual. 
In summary, we propose that the p16INK4a/RB pathway has a key role in 
genome maintenance, through the restriction of the proliferation of cells that are a 
chronically exposed to low amounts of RS. The working model would then be 
summarized as follows. Upon the activation of oncogenes, tumor cells undergo 
promiscuous and uncontrolled proliferation, giving rise to a persistent exposure to 
RS. The INK4a/ARF locus would then be activated upon the continuous presence of 
RS. Upon expression of p16INK4a and p19ARF, p16INK4a/RB and p19ARF/p53 pathways 
will restrain the growth of the (pre)malignant cells through the activation of 
senescence. However, in cells with a mutated INK4a/ARF locus this barrier would 
be abrogated. As a result, premalignant cells would be able to grow even in the 
presence of high levels of RS. Given that RS stands for ssDNA, which is a source of 
CNV and chromosomal rearrangements, growing in the presence of constant RS 
may eventually lead to genome configurations that favor cancer progression.  
1.1. INK4a/ARF locus activation  
At this point, it remains to be understood how a persistent exposure to low 
doses of RS leads to the activation of the INK4a/ARF locus. However, different 
reasons suggest that this activation is not dependent on ATR. First, the activation 
of INK4a/ARF in response to RS requires several days, which contrasts with the 
immediate activation of the ATR dependent RS-response. Second, ATR inhibition 
or hypomorphism lead to increased levels of p16INK4a and p19ARF. Finally, it was 
previously shown in our group that a chronic activation of ATR is able to induce 
senescence in an INK4a/ARF independent manner (Toledo et al., 2008). This last 
piece of evidence formally proves that ATR-induced senescence is not dependent 
on INK4a/ARF. If not ATR, how a chronic exposure to RS ends up activating the 
locus still is an open question. We should note, though, that understanding how 
oncogenes trigger the activation of the INK4a/ARF locus remains unsolved after 
several years since its discovery.  
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Expression of the INK4a/ARF locus can be induced by several means. First, a 
wide range of harmful stimuli, such us UV light, ROS, IR, chemotherapy or 
nucleolar stress  have been reported to induce p16INK4a and/or p19ARF expression 
both, in vitro and in vivo (Sherr, 2012). The nucleolus is a non-membrane bound 
structure found in the nucleus of cells, which transcribes and assembles ribosomal 
RNA (rRNA). A number of cytotoxic compounds, abnormal metabolic conditions, 
and physical insults can alter nucleolar structure and function. In this scenario, 
p19ARF protein binds MDM2, leading to p53 activation and cell-cycle arrest. 
Moreover, p19ARF has also been proposed to function independently of p53 to 
attenuate ribosome trafficking to the cytoplasm (Sherr, 2006). If or how RS can 
promote nucleolar stress remains unresolved. However, given that the rDNA is one 
of the biggest repeats of the human genome it should be preferentially affected by 
RS. 
Second, a number of cancer-related proteins are known to induce the 
expression of the different components of the INK4a/ARF locus. The RAF–MEK–
ERK kinase cascade is one of the best understood pathways that affect INK4a/ARF 
expression. This signaling pathway is of great importance given the high frequency 
of homozygous INK4a/ARF deletions in melanoma, the majority of which harbor 
mutations in the RAF–MEK–ERK signal transduction cascade (Sherr, 2012). In the 
case of MYC, it has been proposed that it may bind directly the INK4a/ARF 
promoter (Gil and Peters, 2006). The inverse correlation between p16INK4a 
expression and RB status in human cancer cell lines raised the question of whether 
the locus could also be regulated by members of the E2F family, that regulate the 
cell cycle progression. In fact, both the p16INK4a and p19ARF promoters harbor 
putative E2F binding sites (Sherr, 2012). However, and at least in MEF, oncogenes 
are capable of activating INK4a/ARF expression regardless of E2F1 or E2F2 
(Palmero et al., 2002). Finally, it is known that members of the AP1 family of 
transcription factors can also regulate the INK4a/ARF locus, although it is difficult 
to present a simple picture of their activities given the fact that they are extremely 
pleotropic (Gil and Peters, 2006).  
 On the other hand, repressors of the expression of INK4a/ARF have also 
been identified. For example, the polycomb group (PcG) genes (BMI-1, Cbx7, 
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Mel18) have been shown to repress the expression of the entire locus. BMI-1 is 
required for stem cell maintenance, and Bmi1 deficiency in mice has been 
associated with a failure in the maintenance of the renewal of stem cells. 
Importantly, this phenotype can be partially rescued by INK4a/ARF deficiency 
(Molofsky et al., 2005). 
Finally, although DNA replication and transcription are generally considered 
independent processes, coupling of the processes has been described in yeast. A 
molecular connection between DNA replication and the transcription of the 
INK4a/ARF locus has also been reported (Gonzalez et al., 2006).  
Whether the activation of the INK4a/ARF locus in response to RS involves 
any of the mechanisms summarized above is still not known. At this point, we can 
only rule out that this induction is mediated directly by the ATR kinase. Still, the 
finding of RS-induced senescence reveals an important role for the INK4a/locus in 
limiting the growth of cells harboring RS, as it could frequently occur in cancer. 
2. The DDR and cancer  
Genome integrity maintenance is an essential part of DNA metabolism. In 
healthy cells, DNA lesions activate a number of responses that lead to DNA repair 
or the elimination of the cell if damage is irreversible. Tumoral cells, in contrast, 
present high levels of chromosomal aberrations. These aberrations come together 
with the deregulation of several pathways. In fact, several alterations of the DDR 
machinery have been found in different types of cancer. For instance, mutations in 
BRCA1 and BRCA2 genes, involved in HR, were the first ones to be found 
associated with familiar cases of breast and ovarian cancer.  
The DDR-associated checkpoint response has been proposed to work as an 
anticancer barrier during the initial stages of cancer development (Bartkova et al., 
2006; Halazonetis et al., 2008). However, besides its checkpoint role, it is also 
possible that its tumor suppressive role might derive from deficiencies in DNA 
repair. For instance, germ-line mutations in HR-repair genes BRCA1 and BRCA2 
confer a high risk of breast cancer development. In these cases of familiar breast 
cancer, where DNA repair deficiencies seem to be the driver of tumorigenesis, 
mutations on ATM and CHK2 have also been reported. 
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Regardless of its repair function, the current model suggests that it is the 
activation of p53-dependent checkpoint and/or apoptotic responses what would 
be the key role of the DDR as a cancer barrier. In fact, activation of the DDR has 
been reported in early cancer lesions, where it could be protecting against tumor 
expansion (Bartkova et al., 2005; Gorgoulis et al., 2005). For instance, 
phosphorylations of γH2AX, CHK2 or ATM have been reported in precancerous 
lesions, suggesting the presence of an activated DDR. In this scenario, the 
subsequent inactivation of components of the DDR may allow the malignant 
progression of the initial lesion. The prevalence of p53 and, to a lower extent, p53 
mutations in advanced stages of cancer seems to favor this view (Halazonetis et al., 
2008). Moreover, the absence of a proficient DDR will increase mutation rates and 
therefore further promote tumor plasticity. In what regards specifically to RS, it is 
worth mentioning that CNV are a hallmark of cancer cells that arise as a result of 
RS (Arlt et al., 2012), and which can also facilitate tumor evolution.  
Oncogene-induced DNA damage is thought to occur through the generation 
of RS. However, how oncogenes generate RS is still not known. Several, non 
exclusive, options have been proposed so far. First, oncogene expression may lead 
to promiscuous S entry leading to an imbalanced replication process and RS. 
Second, the unrestrained proliferation induced by oncogenes can lead to the 
exhaustion of dNTP pools, which is another source of RS (Bester et al., 2011). 
Finally, oncogene expression has also been associated with increased firing of 
replication origins which can impair replication fork progression and promote 
breakage at replication forks (Jones et al., 2012). 
2.1. ATR and cancer 
Accordingly to the previous point, and given that RS leads to ATR/CHK1 
activation, this pathway may play an important role in suppressing RS in cancer. 
To explore the impact of ATR in cancer, ATR-Seckel mice, which have severely 
reduced ATR levels and an extremely low cancer frequency, have been previously 
used in combination with different cancer models.  
The first model to be considered was the p53 deficiency. It had been 
previously reported that other progeria models, different from ATR-Seckel mice, 
Discussion 
101 
 
showed an alleviation of their ageing phenotypes upon p53 loss (Rodier et al., 
2007). However, loss of p53 aggravated the phenotype of both, ATR-Seckel cells 
and mice. At the cellular level, p53 deletion in ATR-Seckel MEF gave rise to a 
dramatic loss in cellular viability as well as an increase RS.  In mice, the absence of 
p53 dramatically decreased the birth ratios of ATR-Seckel mice and led to an 
exacerbation of the progeroid phenotype on the few mice that were born. This 
synthetic lethality was associated to an increase in RS and cell death levels during 
embryonic development (Murga et al., 2009). The explanation to this paradox 
derives from the role of p53 in restricting S phase entry. In the absence of p53, the 
more promiscuous S phase entry would be particularly deleterious in the context 
of a limited ATR pathway. If this model were to be correct, we predicted that ATR 
hypomorphism should also be synthetic lethal with other mutations that promote 
S phase entry. 
To investigate this possibility, Eμ-MYC mice were crossed with ATR-Seckel 
mice. Eμ-MYC mice die prematurely due to the development of B-cell lymphomas 
that show abundant levels of DNA damage. Once again, the presence of the MYC 
transgene significantly limited the viability of ATR-Seckel mice. This observation 
revealed that MYC overexpression was having an effect on embryonic development 
in the context of reduced ATR levels. Accordingly, Eμ-MYC showed an increased 
number of apoptotic cells on ATR mutant embryos, accompanied by a higher 
incidence of cells presenting RS. This generalized synthetic lethal interaction 
between MYC and ATR was unexpected given that MYC overexpression was 
thought to be restricted to B cells in the Eμ-MYC model. However, widespread 
overexpression of the oncogen was found in transgenic embryos. Besides its 
impact on the number of ATR-Seckel mice that were born, and even though Em-
MYC transgenic ATR-Seckel mice die at about the same age as Eμ-MYC, lymphomas 
were never observed on Eμ-MYC mice that were hypomorphic for ATR (Murga et 
al., 2011). Most importantly, established Eµ-MYC lymphomas were shown to be 
very sensitive to CHK1 inhibitors, due to the accumulation of very high doses of RS. 
We now know that ATR inhibitors are also very efficient as a therapy for MYC 
induced lymphomas in mice (Murga et al, unpublished). 
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These series of evidences suggested a model in which a limited activity of 
ATR is synthetic lethal with mutations that promote RS. The implications of such a 
model are of great importance, especially in designing a rational use of ATR and 
CHK1 inhibitors in the clinic, by directing their use to tumors presenting high 
levels of RS. 
2.1.1. ATR and fragile site stability 
Common fragile sites (CFS) are specific and conserved regions of the genome 
that are normally not broken (also known as “silenced”), but that tend to be break 
(what is known as “express”) spontaneously, and even more in the presence of RS. 
Importantly, these sites have been shown to be involved in chromosome 
rearrangements – such us copy number variations (CNVs)- in cancer cells (Casper 
et al., 2002). The reasons of CFS breakage are still not clear. They tend to occur at 
heterochromatic, late-replicating areas of the genome, which show a low density of 
replication origins (Hellman et al., 2000; Le Beau et al., 1998), or that arise due to 
conflicts between replication and transcription, which is more frequent at large 
genes (Helmrich et al., 2011). Notweorthy, ATR was the first gene to be known that 
plays a role in the suppression of CFS expression (Casper et al., 2002).  
CFS are also associated with CNVs. As mentioned, RS can drive the formation 
of CNVs, preferentially at CFS (Arlt et al., 2011a). In fact, it has been shown that 
hydroxyurea (HU) and aphidicolin (APH) –two RS-inducing agents- produce CNVs 
that overlap with fragile sites in MEF (Arlt et al., 2009; Arlt et al., 2011b). Although 
HU and APH use different mechanisms to induce RS, both give rise to CNVs with 
similar frequency, size and distribution; identical to many normal and pathogenic 
CNVs. Altogether, these data strongly suggest a common mechanism mediated by 
RS for the formation of CNVs (Arlt et al., 2012). Moreover, hotspots with a high 
frequency of CNVs were detected and mapped, and they match with the location of 
chromosomal fragile sites (Arlt et al., 2011b).  
Finally, it is worth mentioning that besides CFS, a new class of Early 
Replicating Fragile Sites (ERFS) has been recently discovered (Barlow et al Cell 
2013). Importanly, ERFS are also associated with recurrent hotspots of genome 
rearrangements in cancer, and their stability is also maintained by the action of 
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ATR. Altogether, ATR plays a critical role in the suppression of RS, which can 
contribute to cancer through the generation of chromosomal rearrangements such 
as CNV, which show a preference to occur at spontaneous fragile sites. 
2.2. ATR inhibitors as a potencial anticancer therapy  
Although ATR or CHK1 heterozigosity predispose to tumor onset, ATR 
(Toledo et al., 2011b) and CHK1 (Tao and Lin, 2006) inhibitors have been 
proposed for cancer treatment. This paradox is explained by the analysis of CHK1 
and ATR levels. Whereas half of their normal amounts will generate small doses of 
RS that can facilitate tumor evolution, a stronger inhibition of ATR and CHK1 will 
generate so much RS that it would be toxic for fast replicating tumoral cells. This 
would be particularly true for tumors with mutations that generate high loads of 
RS, which would be particularly sensitive to ATR or CHK1 inhibitors (Figure1). 
 
Figure 1. Rationale for ATRi and CHK1i use in cancer treatment Promiscuous proliferation 
increases cellular RS, which is a hallmark of tumoral cells. If we inhibit the ATR/CHK1 pathway, RS 
repair will be impaired. This will constitute a major problem to cancer cells that already show high 
RS levels. When we treat these cells with ATRi or CHK1i, RS accumulation will reach toxic levels, 
leading to cell death. Healthy cells, on the other hand will not be affected since they are usually not 
replicating or doing it at a slow pace. 
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2.3.1. How do ATR and CHK1 inhibitors kill cancer cells? 
The main mechanism through which we propose that ATRi may kill cancer 
cells is the accumulation of lethal amounts of ssDNA. This is particularly risky 
given that ATR and CHK1 also control the G2/M checkpoint. Hence, ATR or CHK1 
inhibitors would lead to the entry into mitosis of cells that have not completed 
replication, leading to mitotic catastrophe and a kind of cell death that would be 
very difficult to suppress. In addition to this problem, recent data have suggested 
that unreplicated regions of the genome might be cleaved by structure-specific 
endonucleases like Mus81 or Gen1, which would be also activated in mitosis. 
Accordingly, it has been reported that the use of CHK1i or ATRi abrogates the 
G2/M checkpoint and leads to the presence of micronuclei or completely 
fragmented nuclei in cell exposed to IR (Figure2). However, the relative 
contribution of these two pathways (segregation defects or nuclease cleavage) to 
the mitotic catastrophe observed in response to ATR/CHK1 inhibitors is yet not 
known. A screening to find possible resistance mechanisms to ATR and CHK1 
inhibitors is currently being performed in our group with the help of haploid 
mammalian cells. 
 
Figure 2. Typical aberrations observed in IR  treated cells in    the    presence   of    ATRi 
Asterisks and arrows highlight cells with aberrations. Scale bar 5 µm). 
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2.3.2. Are INK4a/ARF or RB mutated tumors good candidates for their 
treatment with ATR or CHK1 inhibitors? 
In contrast to p53 depletion or MYC overexpression, INK4a/ARF deletion or 
T121 expression rescue RS-induced senescence on ATR-Seckel MEF. In sight of 
these data, we wondered whether ATR and CHK1 inhibitors might not be effective 
in tumors carrying mutations in the RB or INK4a/ARF locus, which are very 
frequent in cancer. However, MEF are particularly prone to senescence and most 
replicating cells tend to die in response to DNA damage. In agreement with this, 
and in contrast to the senescence phenotype in MEF, we failed to observe any 
difference in the sensitivity to ATRi of WT and INK4a/ARF-/- splenocytes. 
Moreover, we decided to check the sensitivity to ATRi of different cancer cell lines 
derived from mouse pancreatic tumors, getting a similar result. ATRi were toxic for 
these cells regardless of their p53 or INK4a/ARF status. In addition to this, ATR-
Seckel; INK4a/ARF -/- mice recapitulate all the obvious phenotypes of ATR-Seckel 
mice, which we believe is due to cell-death, rather than senescence, being the main 
determinant of the Seckel pathologies (Figure 2). Altogether, these observations 
suggest the efficacy of ATR or CHK1 inhibitors would not be limited by INK4a/ARF 
or RB status.  
In summary, this work has revealed a new role for the INK4a/ARF locus in 
limiting the expansion of cells suffering from RS, which places this tumor 
suppressor locus as a key player in the maintenance of genomic integrity during 
tumor evolution.  
Discussion 
106 
 
 
Figure 2. Our working 
model 
 INK4a/ARF limits the 
expansion of cells with 
RS, by inducing cellular 
senescence. RS can be 
induced by drugs such as 
HU or ATRi or by different 
oncogenes. The 
accumulation of RS will 
lead to two different outcomes. On the one hand, it will activate a senescence pathway, dependent 
on INK4a/ARF, through an unknown mechanism. On the other hand, high RS doses will give rise to 
cell death through apoptosis and mitotic catastrophe. Of the two consequences of RS accumulation, 
senescence will be of importance in certain cell types – i.e. MEF- ; whereas cell death will define the 
in vivo phenotype of the mouse.  
3. ATR is essential at the cellular level 
In contrast to ATM, ATR is essential at the single cell level (Brown and 
Baltimore, 2000). Based on our results on ATR-Seckel MEF senescence, we tried to 
rescue the lethality associated to ATR nullizigosity through the expression of T121. 
Whereas this strategy did not work, we are currently exploring other possibilities 
that could rescue ATR deficiency in our laboratory. In    S.cervisiae,  deletion of the 
ATR orthologue MEC1 is also lethal. However, even though  MEC1 is an essential 
gene, the lethality can be rescued by  increasing dNTP levels  (Desany et al., 1998).  
Moreover, MEC1 could also be rescued by the concomitant deletion of Sml1  
(Suppresor  of  Mec  Lethality 1),  a negative  regulator of the ribonucleotide 
reductase  (RNR). The role of this pathway in mammalians remains largely 
unexplored. However, we already know that ATR-Seckel MEF show a decrease in 
RS levels and a partial growth rescue when extra nucleosides are added to the   
media. Moreover, the median lifespan of ATR-Seckel mice can be doubled when 
crossed with a transgenic mouse model of the RNR complex (Lopez-Contreras et al 
unpublished data). Hence, preliminary evidence suggests that the essential role of 
ATR in mammals can also be related to its role in promoting dNTP biosynthesis.  
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CONCLUSIONS 
1. A chronic exposure to RS activates the expression of p16INK4a and p19ARF. 
2. Deletion of INK4a/ARF facilitates the growth of MEF that are chronically 
exposed to low doses of RS-inducing agents such as ATRi or HU.  
3. INK4a/ARF depletion or genetic deletion rescues senescence on ATR-Seckel 
MEF, without rescuing ATR levels or presence of RS on these cells. However, 
depletion or deletion of p16INK4a or p19ARF alone is not sufficient to rescue growth 
on ATR mutant MEF.  
4. Deletion of INK4a/ARF does not have an impact on viability or lifespan of 
ATR-Seckel mice. 
5. ATR-Seckel embryos present widespread apoptosis but no clear signs of 
senescence, which suggests a limited role of senescence on the Seckel phenotype.  
6. INK4a/ARF deletion does not modify the cytotoxic effects of ATR inhibitors 
in vitro or CHK1i administration in vivo. 
7. Cancer cell lines with a high number of CNVs present low levels of p16INK4a. 
8.  Expression of the T121 fragment from the SV40 large T antigen, which 
inhibits retinoblastoma but not p53, is able to immortalize ATR-Seckel MEF. 
9. Expression of T121 is not able to rescue the viability of ATR nullizygous 
cells. 
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